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Abstract 
Autoimmune Addison’s disease (AAD) is characterized by an autoimmune destruction of 
hormone producing cells in the adrenal cortex. The pathogenesis of the disease involves 
autoantibodies and autoreactive T-cells against 21-hydroxylase, an enzyme involved in the 
production of adrenal gland hormones. No cure exists for the disease and these patients are 
dependent on life-long replacement therapy causing reduced quality of life and a higher risk of 
death. It is therefore important to develop new treatment options that can improve patients’ 
quality of life, restore self-tolerance and possibly reverse the autoimmune reaction. CTLA4, 
encoding a vital inhibitory molecule involved in T-cell signalling, is a possible susceptibility 
gene for disease development. Abatacept is a soluble CTLA4 molecule, which have been 
approved for use in the treatment of the autoimmune disease rheumatoid arthritis, blocking a 
co-stimulatory signal necessary for complete T-cell activation, thus reducing proliferation and 
the production of cytokines. Conflicting results have been shown in studies examining the effect 
of abatacept on regulatory T-cells (Tregs) in autoimmune disorders.  
 
We hypothesized that treatment with abatacept (CTLA4-Ig) in AAD patients could increase the 
number of Tregs and suppress the autoimmune response by affecting the inhibitory function of 
CTLA4. To explore this, we developed a method for screening the effect of this drug on T-cells 
in AAD patients and healthy controls at the KG Jebsen Center for Autoimmune Diseases. The 
methodology included cell culture of peripheral blood mononuclear cells (PBMC), flow 
cytometry, quantitative polymerase chain reaction (qPCR) and enzyme-linked immunosorbent 
assay (ELISA).  
 
We succeeded in developing an in vitro method on primary cells that can be used to screen the 
effect of abatacept on T-cells in patients with AAD. Although our study is considered to be 
preliminary due to a low number of patients, our results indicate that abatacept affects 
proliferation and the fraction of live cells in both patients and controls, and had a varying effect 
on the Treg population in both cohorts. IFN-g levels were higher in AAD patients than in 
controls both before and after drug treatment, but both groups showed decreased production of 
IFN-g as a consequence of abatacept. Future studies should include a higher number of 
individuals to be investigated in order to reveal treatment-specific differences between patients 
and controls in regard to abatacept treatment.    
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Abbreviations 
AAD Autoimmune Addison’s Disease  
ACTH Adrenocorticotropic hormone  
AIRE Autoimmune regulator  
APC Antigen presenting cell 
APS-1 or 2 Autoimmune Polyendocrine Syndrome Type 1 or 2 
CD Cluster of differentiation  
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CFSE Carboxy fluorescein diacetate succinimidyl ester 
CTLA4  Cytotoxic T-Lymphocyte Associated Protein 4 
DMSO Dimethyl sulfoxide  
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FACS Fluorescence activated cell sorting 
FasL/FASLG Fas ligand/Fas Ligand Gene 
FCS Forward light scattering 
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GWAS Genome wide association study  
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ICOS Inducible T-cell co-stimulator 
IFN-g Interferon g 
IL Interleukin  
IPEX Immune dysregulation, polyendocrinopathy, 
endocrinopathy, X-linked 
MHC Major histocompatibility complex 
mTEC Thymic medullary epithelial cell 
PAMPs Pathogen-associated molecular patterns 
PBMC Peripheral Blood Mononuclear Cell 
PBS Phosphate-buffered saline  
(q)PCR (Quantitative) Polymerase Chain Reaction  
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SSC Side light scattering  
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TGF-b Transforming Growth Factor b 
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TNF-a Tumor necrosis factor a 
Treg(s) Regulatory T-cell(s)  
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1. Introduction  
1.1. The immune system 
The immune system is the human body’s main defence against threats from the outside and 
consists of two main parts; innate and adaptive immunity (1). When a pathogen (bacteria, virus 
etc.) enters the body, it meets its first obstacle in the innate immune system (2). This is made 
up of chemical and physical barriers, acute phase proteins, the complement system and different 
types of cells, such as dendritic cells and macrophages, that can respond to the presence of 
pathogen-associated molecular patterns (PAMPs) (2, 3). Looking at the aspect of time, the non-
specific innate response sets in almost immediately after encountering a pathogen, which is of 
major importance as many bacteria can double in number within a short amount of time (2, 4). 
The components of the innate immune system do not generate immunological memory and 
some of its main missions are to detect foreign substances and produce signalling molecules 
(cytokines, chemokines) that will attract other immune cells to an infection site and alert the 
adaptive immune system (5, 6). An adaptive response is then initiated and consists of a humoral 
and a cellular branch, mediated by B- and T-lymphocytes, respectively (7).  
 
1.2. B-cells 
B-cells develop and become fully mature in the bone marrow (1). B-cells are important for the 
function of T-cells, as they can act as antigen presenting cells (APC) (8), while T-cells 
contribute to B-cell function by stimulating them to differentiate and proliferate (9). Unlike T-
cells, B-cells do not depend upon antigen presentation, as they can eliminate extracellular 
pathogens on their own through the production of antibodies (1), which starts after the activated 
B-cells have differentiated into antibody producing and secreting plasmablasts and/or plasma 
cells (10). Also, these antibodies have a dual role as they will work to prevent development of 
an infection, but they could also cause tissue damage in organ transplants and autoimmunity 
(11). After eliminating a foreign disease-causing substance, a fraction of activated B-cells will 
turn into memory B-cells, and if the host is infected by the same pathogen at a later point in 
life, the immune response will be much faster (12).  
 
1.3. T-cells  
T-lymphocytes develop from hematopoietic stem cells in the bone marrow, before the T-cell 
progenitors travel to the thymus to continue their development (1). There are two different 
subgroups of conventional T-cells; cluster of differentiation (CD) 4  T-helper (Th) cells (further 
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divided in the effector T-cells Th1, Th2 and Th17) that produce cytokines important for the 
activation of B-cells and for the function of CD8 T-cells, and CD8 cytotoxic T-cells that can 
directly eliminate cells infected by 
intracellular pathogens, such as viruses (13-
17) (Fig. 1). T-cells are not able to recognize 
foreign substances on their own; fragments 
of antigens have to be presented bonded to 
major histocompatibility complex 
molecules (MHC) on an APC, before the T-
lymphocytes can be involved in an immune 
response (18).  
 
Also important for T-cell function is the T-
cell receptor (TCR) (19). For the majority of 
T-cells it consists of two chains, a and b, 
both of which have a constant, variable, 
diversity and joining region, and 
rearrangements of these make it possible for  
T-cells to respond to almost every pathogen threatening the host (1, 19). Rearrangement of the 
TCR is important in the formation of CD4+ and CD8+ cells in the thymus, ensuring MHC class 
restriction (19). Signalling through the TCR is also dependent on the formation of a complex 
with CD3, containing a cytoplasmic part necessary for downstream signalling and activation 
(20-22), but  also require interaction with a co-receptor; CD4 for the helper cells responding to 
MHC class II molecules and CD8 for cytotoxic cells responding to MHC class I molecules (23, 
24) (Fig. 1).  
 
1.4. Thymic development of T-lymphocytes 
The thymus is a lymphoepithelial organ located in front of the heart, but behind the chest bone, 
and is the main site for T-cell development (7). After migrating from the bone marrow to the 
thymus, early T-cell precursors are in a double negative (CD8-CD4-) state, before signaling 
through a pre-TCR complex, which is important for maturation of the cell strain, takes the 
progenitor cells/thymocytes to a double positive (CD8+CD4+) state (25-27) (Fig. 2). The next 
step is for the double positive CD8+CD4+ thymocytes to develop into either CD4+ or CD8+ 
single positive cells, a process that rely on interactions with MHC class I or MHC class II 
Figure 1: Antigen presentation and co-receptors. 
Presentation of antigen through MHC-molecules is required for 
the initiation of the T-cell immune response. CD4+ cells 
recognize antigens presented by MHC II, while CD8+ cells 
respond to antigens presented by MHC I. This figure contain 
elements from Servier Medical Art by Servier, 2020. 
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molecules (28) (Fig. 1). Further, positive selection in the thymic cortex will select the cells that 
bind self-MHC class I or II, to become single-positive thymocytes (29) (Fig. 2). The positive 
selected thymocytes then migrate to the thymic medulla, where negative selection will lead to 
the deletion of thymocytes that react to strongly to self-peptides presented by MHC class I or 
II (29). Negative selection is an important step in T-cell development that has been shown to 
happen through programmed cell death, also known as apoptosis, and might be caused by the 
interaction between Fas and its ligand (FasL) (30-32). 
 
A protein of major importance in negative selection and the discrimination between self- and 
non-self is the autoimmune regulator (AIRE) (33). This protein can be found in thymic 
medullary epithelial cells (mTECs), where it controls the expression of peripheral tissue-
restricted antigens, such as insulin, and present them to precursor T-cells (33). The importance 
of accurate negative selection is exemplified by a mutation in or lack of expression of AIRE, 
which leads to the development of autoimmune polyendocrine syndrome (APS) type 1 (34). 
This is a monogenic disorder characterized by the presence of two out of three components; 
Addison’s disease, hypoparathyroidism and chronic mucocutaneous candidiasis (34). It has also 
been shown that AIRE plays a role in the thymic formation of another subset of CD4+ T-cells 
expressing Forkhead Box P3 (FOXP3), called regulatory T-cells (Tregs) (35) (section 1.5). 
After completing their development in the thymus, naïve CD4+, CD8+ and Treg cells will 
relocate to the periphery and start “patrolling” the environment for invaders (36, 37) (Fig. 2).    
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Figure 2: Development of T-cells. Bone marrow stem cells migrate to the thymus and serve as double negative T-cell 
progenitors. Rearrangement of the TCR-b-chain gives rise to double positive thymocytes, which in turn becomes CD4+ or 
CD8+ single positive cells. These will further differentiate, in the periphery, to different subpopulations of T-cells dependent 
on cytokine production and secretion. IFN-g and IL2 give rise to Th1 cells, IL4 causes differentiation into Th2 cells, while IL6 
and TGF-b stimulates Th17 cell differentiation.   
 
1.5. Regulatory T-cells  
Tregs are a subpopulation of CD4+ T-lymphocytes that can control the effect of other immune 
cells and thus have a crucial function in the maintenance of self-tolerance (38, 39). Commitment 
to the Treg cell lineage is thought to depend on the strength by which the cell binds the self-
peptide/MHC-complex in the thymus; too high affinity will trigger negative selection, low 
affinity will cause generation of conventional naïve T-cells and an affinity between these outer 
limits will give rise to a fraction of FOXP3 expressing cells, known as thymic derived Tregs 
(tTregs) (40-42). Not all regulatory T-cells are formed in the thymus; a subtype known as 
peripheral Tregs (pTregs) arise from conventional CD4+ T-lymphocytes outside the thymus 
(37). Precursors of both tTregs and pTregs depend upon signalling through CD28 (section 1.6) 
to become FOXP3 expressing Tregs, for survival and for maintenance of homeostasis outside 
the thymus (43-45).   
 
Different mechanisms as to how Tregs mediate suppression of the immune response have been 
suggested (37). There are at least four main pathways that these cells could follow: The first is 
controlled by, amongst others, cytotoxic T-lymphocyte associated protein 4 (CTLA4), 
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constitutively expressed by Tregs, through cell-cell-contact (37, 46). The function of CTLA4 
will be described later (section 1.8). A second possible mechanism of action is caused by the 
constitutive expression of CD25 by Tregs, which make them a contender to effector T-cells in 
the race for the cytokine interleukin (IL) 2 (37). Further, it has been found that IL2, as for 
conventional T-cells, is important for the function and survival of Tregs (47-49). The third 
mechanism involves the production and secretion of cytokines, such as IL10 and transforming 
growth factor b (TGF-b), which will affect function, activation and the inhibitory properties of 
Tregs (37, 41). Finally, it has been suggested that Tregs have the ability to cause direct 
apoptosis, due to the production of granzymes (37, 50). 
 
Tregs are one of the main characters among the peripheral tolerance mechanisms, working to 
protect the body against autoimmunity and also play an important role in limiting an unwanted 
excessive immune reaction (38). If the peripheral tolerance mechanisms fail, autoimmunity 
could arise either as a consequence of malfunctioning Tregs, reduced frequency of Tregs or due 
to the ability of conventional T-cells to resist Treg mediated suppression (51, 52). 
Malfunctioning Tregs can lead to development of autoimmunity, as mutations in the Treg key 
regulator FOXP3 causes immune dysregulation, polyendocrinopathy, enteropathy, X-linked 
(IPEX) (53, 54). The role of Tregs in self-tolerance and autoimmunity make them a potential 
target for therapy (55, 56).  
 
1.6. T-cell activation 
For a T-cell to be able to perform its duty in the immune response, it has to be activated (57).  
This process starts with the interaction of the TCR with the antigen-MHC-complex on the APC 
(57). The APCs present fragments of the antigen through MHC class I or II on their cell surface, 
which is then recognized by a CD8 or CD4 cell, respectively, and the first step in the activation 
process is completed (23, 24, 57) (Fig. 3, modified from (58)). For proliferation and 
differentiation to take place, a co-stimulatory signal is necessary (57). Furthermore, it has been 
shown that lack of co-stimulation will render the cell anergic, meaning that it is in a state of 
unresponsiveness (59). CD28 is a molecule on the T-cell surface that can provide such a co-
stimulatory signal (60) (Fig. 3). CD28 will bind the co-stimulatory ligands CD80 and CD86 on 
the APC, and with the TCR-MHC/antigen binding already present, the T-cell is activated (43) 
(Fig. 3).  
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Activation leads to upregulation of the IL2-receptor 𝛼 chain (CD25) on the T-cell surface, and 
the production and binding of IL2 stimulates further proliferation and differentiation (7). The 
effector function of the CD4+ T-cells are decided by the production of cytokines by the APC; 
interferon g (IFN-g) and IL12 promotes differentiation into Th1 cells, IL4 promotes Th2 cells, 
while IL6 together with TGF-b have been shown to give rise to Th17 cells (61) (Fig. 2). IFN-g 
plays a role in the immune response as it has been shown to increase the expression of MHC 
class II molecules on certain cells (62, 63). In addition, production of IFN-g by Th1 cells will 
contribute to the activation of macrophages and the initiation of an antipathogenic response 
(64).  
 
Figure 3: Activation of CD4 T-cells require ligation of both the TCR and CD28. Signal 1 shows binding of TCR to the 
antigen-MHC class II-complex on the APC. Signal 2 is co-stimulatory, and lack of this signal will take the cell into a state of 
unresponsiveness. Cytokine production by the APC will determine the effector function of the CD4 T-cell. Further, the activated 
cells will expand, proliferate and initiate an immune response against a pathogen. Modified from Gutcher et al., 2007 (58). 
This figure contain elements from Servier Medical Art by Servier, 2020. 
 
1.7. Cellular markers of regulatory and conventional T-cells 
Tregs are characterized by a set of intra- and extracellular markers, that can be used to 
characterise these cells by flow cytometry (65). Some of these markers, and conventional T-
cells markers, will be briefly described below. Flow cytometry will be described in section 3.4.  
 
CD3 
CD3 is located on the surface of T- cells and plays an important role in T-cell signalling and 
activation (20). It forms a complex with the TCR, enabling generation of a signal necessary for 
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downstream signalling and activation (20, 22).  
 
CD4 
CD4 is a T-cell co-receptor located on the cell surface of T-helper cells, that can recognize 
fragments of antigen presented through MHC class II (23).  
  
CD25 
CD25, also known as the IL2 receptor 𝛼-chain, is upregulated on the cell surface of 
conventional T-cells after antigen stimulation and could be used as a marker of T-cell activation 
(66). It is also constitutively expressed by Tregs (37, 67) (section 1.5).    
 
CD31 
CD31 can be used to identify naïve T-cells due to the expression of this protein by T-cells that 
have recently left the thymus (68). 
 
CD39  
CD39 is a surface marker found present on Tregs and has been found to be particularly, but not 
exclusively, expressed by activated Tregs, and has been suggested to play a role in their 
suppressive function (65, 69, 70). 
 
CD152 
CD152,  also known as CTLA4, is constitutively expressed by Tregs, and involved in one of 
the proposed mechanisms as to how these cells can mediate suppression of the immune 
response (37, 46) (section 1.5). CTLA4 will be further described in section 1.8.  
 
CD304 
The cell surface located CD304, also known as Neuropilin-1, has been suggested as a marker 
of Tregs (71). It has also been shown as a possible T-cell activation marker, and not as a distinct 
Treg marker (72). Two studies have shown that CD304 can be used to discriminate between 
tTregs and pTregs in vivo using animal models (73, 74).    
 
CD45RA 
CD45RA is a cell surface marker that can be used to separate naïve/resting Tregs and T-cells 
from those that have been activated (65, 75, 76).  
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Helios  
Helios is another intracellular marker of Tregs (65). Helios is expressed by Tregs formed in the 
thymus, and within the peripheral tTreg population there are both Helios positive and negative 
cells with suppressive properties (77, 78). 
 
FOXP3 
Another intracellular marker is FOXP3, a transcription factor indispensable in the thymic 
development of Tregs (54). The intracellular expression of FOXP3 by Treg makes  it possible 
to discriminate them from activated conventional T-cells, hence an essential marker for Tregs 
(65, 79).  
 
1.8. CTLA4 
After T-cell activation the protein receptor CTLA4 is expressed on the cell surface, together 
with CD28 (80). It has been suggested that its expression is induced by signalling through the 
TCR and co-stimulation through CD28 (81, 82). CTLA4 “competes” with the latter molecule 
on ligating CD80/CD86 on the APC, and will “win” due to higher affinity for the ligands (83, 
84). Unlike CD28, the binding of CTLA4 provides a co-inhibitory signal, that will cause 
inhibition of T-cell activation and as a consequence halt the immune response (83, 85, 86) (Fig. 
4, modified from (87)). The inhibitory properties of CTLA4 have been confirmed by 
experiments involving CTLA4-deficient mice, who develop lymphoproliferative disorders after 
a short period of time (88) and it has also been shown that CTLA4 is important for the 
suppressive role of FOXP3-expressing Tregs (89). Mutations in CTLA4 have been found in 
humans, leading to, amongst others, lymphoproliferation and hypogammaglobulinemia (90). 
The inhibitory properties of CTLA4 makes it a promising target in the treatment of certain types 
of cancer, and agents blocking CTLA4, also called check-point inhibitors (e.g. Ipilimumab) are 
now widely used in the treatment of cancer (91). A known side effect of these drugs is the 
development of autoimmune disease, including Addison’s disease or primary adrenal 
insufficiency (92, 93), which will be discussed in detail later.  
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Figure 4: CTLA4 provides a co-inhibitory signal resulting in decreased T-cell activation. T-cell activation depends on 
signalling through the TCR and ligation of CD28. After activation, CTLA4 is upregulated on the T-cell surface. CTLA4 will 
bind CD80/86 on the APC with higher affinity than CD28 and has an inhibitory effect on the T-cell. This leads to decreased T-
cell activation, proliferation and differentiation. The result is a decreased immune response. The figure contains elements from 
Servier Medical Art by Servier, 2020. Modified from Lacouture et al., 2014 (87). 
 
There are several ways by which CTLA4 could exert its inhibitory function, in addition to 
“competing” with CD28 (94). One suggested mechanism is that CTLA4 prevents ligation of 
CD28 by removing CD80/CD86 from the APC in a process known as trans-endocytosis (95). 
Another suggestion is that CTLA4 has the ability to act as a modulator of the threshold required 
for signalling through the TCR and activation of T-cells (96, 97). Further, CTLA4 has been 
suggested to cause decreased expression of CD80/CD86 through the production of TGF-𝛽 
and/or IL10, and to initiate generation of the enzyme indoleamine-2,3-dioxygenase by binding 
CD80/CD86 on dendritic cells, leading to reduced levels of tryptophan, both of which cause a 
downregulated T-cell response (83, 94, 98). CTLA4 has also been suggested to affect 
phosphorylation of the CD3 zeta chain in the TCR-complex (99), but this theory has been 
questioned as other studies have shown the opposite (100). In addition, polymorphisms in the 
CTLA4 gene have been associated with susceptibility for development of autoimmune disease, 
where CTLA4 acts as a negative modulator by suppressing the immune response (94, 101, 102).   
 
1.9. Autoimmune Addison’s disease 
Autoimmune Addison’s disease (AAD) is an autoimmune disease leading to the destruction of 
cortisol producing cells in the adrenal cortex by the host’s own immune system (103, 104). 
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AAD can exist as an isolated event or it could arise as a part of two different autoimmune 
syndromes; APS-1 or APS-2 (103) (section 1.4). AAD is considered a rare disease compared 
to for instance type 1 diabetes and autoimmune thyroid disease (103), with a prevalence of 144 
per million in Norway (2008) 
(105). Most patients with AAD 
have circulating autoantibodies 
against the enzyme 21-hydoxylase, 
important in the biosynthesis of the 
hormones cortisol and aldosterone 
(105, 106). However, it is 
considered that the autoimmune 
destruction of cells in the adrenal 
cortex could be mediated by self-
reactive T-cells, as autoreactive T-
cells against 21-hydroxylase have 
been found present in AAD patients 
(107-109). Other possible 
mechanisms for development of 
AAD could be viral infections, 
genetic predisposition and use of check-point inhibitors (section 1.8) (92, 104) (Fig. 5). This 
illustrates the complexity of the disease mechanism.  
 
Over time, patients will eventually start developing symptoms of disease, including skin 
hyperpigmentation and an increased hunger for salt, in addition to more diffuse features such 
as tiredness, nausea, low blood pressure and abdominal pain (105, 110). Furthermore, measured 
serum levels of cortisol are low, with an additional high level of adrenocorticotropic hormone 
(ACTH), in the morning (103, 110-112). Patients might also present with decreased levels of 
aldosterone, a hormone important in the body’s mechanism working to maintain a normal salt-
water balance (111, 112). If the disease is left untreated or the medication is insufficient, it may 
lead to the development of acute adrenal crisis, which in turn will lead to hospitalization and a 
need for treatment with intravenous hydrocortisone and saline (110, 112).  
 
Figure 5: Factors that might contribute to the development of AAD in 
humans. Environmental factors, such as a viral infection, or a person being 
genetically susceptible for autoimmunity are thought to be a part of AAD 
pathogenesis. As are the use of check-point inhibitors, autoantibodies and 
autoreactive T-cells. Figure from Hellesen et al., 2018 (104). 
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1.10. Regulatory T-cells and CTLA4 as targets for therapy in autoimmune 
Addison’s disease 
The fact that Tregs play an important role in maintaining self-tolerance and in the prevention 
of autoimmunity is now an established concept (38, 51, 113), but it is not yet known whether 
the frequency and/or function of Tregs is impaired in patients with AAD. What is known is that 
Tregs constitutively express CTLA4 (46) and that it plays a role in the development and 
progression of autoimmune diseases (94, 114). It has also been suggested that variants in the 
CTLA4 gene could increase the risk for development of AAD (115). A 2015 study by Wolff et 
al. looked at the role of CTLA4 in AAD and found a variant that, in the European population, 
is associated with AAD, thus strengthening the fact that CTLA4 plays a part in the pathogenesis 
of the disease (116). A recent genome wide association study (GWAS) including patients with 
AAD from Norway and Sweden has further shown, with genome wide significance, that certain 
variants in the CTLA4 gene predispose to AAD (Eriksson, Røyrvik and Aranda-Guillen et al., 
submitted manuscript). All together these evidences make both Tregs and CTLA4 possible 
targets for therapy in AAD.  
There exists a drug on the marked 
today, abatacept, sold under the brand 
name Orencia (Bristol-Myers Squibb), 
that is a fusion protein made up of  a 
modified constant part of human 
immunoglobulin 1 (IgG1) and the 
extracellular part of human CTLA4 
(117, 118) (Fig. 6). It used in the 
treatment of rheumatoid arthritis, 
psoriatic arthritis and juvenile 
idiopathic arthritis, and works by 
interfering with the co-stimulatory 
signal that T-cells depend upon to 
become fully activated (117) (Fig. 7). Abatacept is available both as prefilled syringes and as a 
powder, where the latter is given to the patient as an infusion (117). Production of abatacept 
involves ovarian cells from Chinese hamsters and the use of recombinant DNA technology 
(117). Common side effects include upper airway infections and reactions at the site of 
infusion/injection (117). More serious infections, such as pneumonia, have also been reported, 
and the development of malignancy/cancer is another possible, but rare, side effect (117).  
Figure 6: Structure of abatacept. Abatacept is a fusion protein as it 
consists of the extracellular part of CTLA4 and a modified constant part 
of human IgG1.The figure contains elements from Servier Medical Art 
by Servier, 2020. Modified from Dubois et al., 2009 (118). 
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Figure 7: Abatacept mechanism of action. Abatacept will block binding of CD28 to CD80/86 on the antigen presenting cell. 
The result is decreased production of cytokines and other inflammatory substances, due to inhibition of T-cell activation, 
proliferation and differentiation. The figure contains elements from Servier Medical Art by Servier, 2020. Modified from 
Dubois et al., 2009 (118). 
 
The mechanism of abatacept has been confirmed by Davis et al., who have shown that the drug 
is a potent modulator of T-cell activation, as treated cells showed reduced proliferation and a 
decreased production of cytokines and interleukins, such as IL2 and IFN-g (119). The effect of 
abatacept/CTLA4-Ig on Tregs in patients with rheumatoid arthritis have also been explored, 
but with conflicting results. One study indicated a lowered amount of Tregs, but with an 
increased regulatory/suppressive function, after treatment with abatacept (120). Another study 
interestingly reported an increased frequency of both T-cells and Tregs as a result of 
administration of CTLA4-Ig (abatacept) (121). Although the results of using abatacept as a 
modulator of Tregs is conflicting and mostly done in systemic autoimmune disorders, the use 
of abatacept has to date not been investigated in regard to AAD.  
 
1.11. Current status  
As elaborated on before, the immune depressor CTLA4, invariably expressed on Tregs (46), 
has been associated with AAD (115, 116) (Eriksson, Røyrvik and Aranda-Guillen et al., 
submitted manuscript). CTLA4 is known to be involved in autoimmunity (94, 102, 114) and 
abatacept, a CTLA4-Ig fusion protein, is approved for use in the treatment of systemic 
autoimmune disorders, like autoimmune rheumatoid arthritis (117). Abatacept has also been 
tested in patients with recent-onset type 1 diabetes mellitus, indicating a delayed reduction in 
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the function of insulin producing cells in the pancreas, for a certain amount of time post-
diagnosis (122, 123). Abatacept has, as far as we know, not yet been tried in patients with AAD 
or polyendocrine syndromes.  
 
There exists, until now, only one treatment option for AAD patients; steroid replacement 
therapy (110, 111). Drugs are normally given as tablets, and it is important for patients to learn 
how to adjust the dosage, especially in stressful situations, like exercising or in the case of an 
infection (110). Studies have been conducted to test administering cortisone as an infusion 
through a pump, similar to the insulin pump used in the treatment of type 1 diabetes, but it has 
been difficult to obtain a precise mimic of the body’s circadian cortisol production (124, 125). 
Due to the unphysiological treatment patients with AAD still suffer from numerous symptoms 
such as lower quality of life (126, 127) and a higher risk of death (128). Also, these patients 
will have to take medications and be taken care of by the specialised health care system for the 
rest of their lives (112). Therefore there is a great need to develop new treatment options, and 
preferably drugs that can redirect the autoimmune pathological reaction, and perhaps even 
reverse disease. 
 
1.12. Hypothesis and aims 
Our hypothesis is that CTLA4-Ig (here, further referred to as abatacept) could be used in the 
treatment of AAD by increasing the number of Tregs and suppress the autoimmune response 
by enhancing the inhibitory function of CTLA4. To examine this, we aimed to develop a 
method for drug screening and examine the effect of abatacept in an in vitro cell system.  
 
Specific aims: 
1. Develop an in vitro cell assay to screen the effect of drugs on T-cells and Tregs in AAD 
patients. 
    
2. Examine the specific effect of abatacept on T-cells in patients with AAD by 
a. Use flow cytometry to examine cell expression of intra- and extracellular 
markers of T-cells and Tregs at the protein level. 
b. Use enzyme-linked immunosorbent assay (ELISA) to examine production and 
secretion of the cytokine IFN-g in activated cells, treated or untreated with 
abatacept.  
 
 21 
3. Examine gene expression in the T-cell signalling pathway in resting cells and in 
activated cells with or without abatacept by quantitative polymerase chain reaction 
(qPCR) at the RNA level.    
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2. Materials 
The following tables show the different chemicals (table 1), equipment (table 2), instruments 
(table 3) and software (table 4) used in this project.   
 
Table 1: Chemicals 
Chemicals Producer Catalog number 
2-Mercaptoethanol  Aldrich Chemistry M6250-100ML 
AB-serum Sigma-Aldrich  H4522-100ML 
Anti-CD3, V500, clone UCHT1 BD BioSciences 561416 
Anti-CD4, Alexa Fluor 700, clone RPA-T4 BD BioSciences 557922 
Anti-CD8, PerCP-Cy5.5, clone SK1 BD BioSciences 565310 
Anti-CD25, PE-Cy7, clone 2A3 BD BioSciences  335824 
Anti-CD31 (PECAM-1), BV785, clone L133 BD BioSciences 744757 
Anti-CD39 (ENTPD-1), PE, clone eBioA1 Invitrogen by Thermo Fisher 
Scientific 
12-0399-42 
Anti-CD45RA , APC-H7, clone HI100 BD BioSciences 560674 
Anti-CD152 (CTLA4), BV421, clone BNI3 Sirigen/BioLegend 369606 
Anti-CD304 (neuropilin-1), BV650, clone 
U21-1283 
BD BioSciences 743131 
Anti-FoxP3, PECF594, clone 236A/E7 BD BioSciences  563955 
Anti-Helios/IKZF2, APC, clone 22F6 BioLegend  137222 
BD Pharm Lyse Lysing Buffer BD Biosciences  555899 
BioWhittaker RPMI 1640 without L-
Glutamine   
Lonza BE12-167F 
Bovine Serum Albumin (BSA) Sigma Life Science A7030-100G 
DEPC-treated water  Ambion AM9922 
DMSO   Sigma-Aldrich D2650 
Ethanol 96% Antibac 6000051 
Fetal Bovine Serum (FBS) Sigma-Aldrich  F7524 
Human BD Fc block BD Biosciences  564220 
Human CD152 [CTLA-4]:Fc Chimerigen/Nordic BioSite CHI-HF-220A4-C500 
IL2  Thermo Fisher Scientific PHC0023 
L-Glutamine  Lonza BE17-605F 
MACS BSA Stock Solution Miltenyi Biotec 130-091-376 
Penicillin-Streptomycin Mixture Lonza 17-602E 
PBS (phosphate-buffered saline) Sigma-Aldrich D8537-500ML 
RNase away  Molecular Bio Products 7002 
RNaseZap  Thermo Fisher Scientific AM9780, AM9782 
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RT2 SYBR Green Rox qPCR Mastermix Qiagen 330521 
Stop Solution for TMB Substrate  BioLegend  423001 
Surface disinfection 75% Antibac 600521 
TaqMan Gene Expression Assay (VIC). Gene 
symbol: B2M 
Thermo Fisher Scientific 4448490 
TaqMan Gene Expression Assay (FAM). Gene 
symbol: CTLA4 
Thermo Fisher Scientific 4331182 
TaqMan Gene Expression Assay (FAM). Gene 
symbol: FASLG 
Thermo Fisher Scientific 4331182 
TaqMan Gene Expression Assay (FAM). Gene 
symbol: ICOS 
Thermo Fisher Scientific 4331182 
TaqMan Gene Expression Assay (FAM). Gene 
symbol: JUN 
Thermo Fisher Scientific  4331182 
TaqMan Gene Expression Master Mix Applied Biosystems/Thermo 
Fisher Scientific 
4369016 
Trypan Blue stain Life Technologies Co T10282 
Tween 20 Sigma-Aldrich P7949 
Water Nuclease Free VWR 7732-18-5 
 
Table 2: Equipment and kits 
Equipment Producer Catalog number 
96-Well Immuno Plates  Thermo Fisher Scientific 6905TS 
384 Well Multiply-PCR Plate skirted, natural  Sarstedt  72.1984.202 
Agilent RNA 6000 Pico Kit Agilent Technologies  5067-1513 
Agilent RNA 6000 Pico Ladder Agilent Technologies 5067-1535 
Agilent RNA 6000 Pico Reagents Agilent Technologies  5067-1514 
ART Barrier Hinged Racked Pipette Tips 
- 1000 µL 
- 300 µL 
- 200 µL 
- 100 µL 
- 20 µL 
- 10 µL 
Thermo Fisher Scientific  
2179-HR 
2070-HR 
2069-HR 
2065-HR 
2149P-HR 
2139-HR 
ART Barrier Reload Insert, Extended Length 
Pipette Tips 
- 1000 µL 
- 20 µL 
- 10 µL 
Thermo Fisher Scientific  
 
2179-05-RI 
2149E-05-RI 
2140-05-RI 
BD Vacutainer CPT  BD 362780/362753 
CellTraceTM CFSE Cell Proliferation Kit  Invitrogen  C34554 
ClipTip Filtered Pipette Tips  Thermo Fisher Scientific  
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- 300 µL 94420518 
ClipTip Non-Filtered Pipette Tips  
- 300 µL 
Thermo Fisher Scientific  
94410610 
CoolCell FTS30  Biocision BCS-170 
Cryogenic Vials  Nalge Company  5000-1020 1.5 mL 
Dead Cell Removal Kit Miltenyi Biotech 130-090-101 
eBioscience Foxp3/Transcription Factor 
Staining Buffer Set Kit  
Invitrogen/Thermo Fisher 
Scientific 
00-5523-00 
ELISA MAX Deluxe Set Human IFN-g BioLegend 430104 
F1-ClipTip Multichannel Pipettes  
- 30-300 µL 
Thermo Fisher Scientific  
4661180N 
Falcon tube  
- 15 mL 
- 50 mL 
VWR  
525-0150 
525-0156 
Finnpipette F1 Multichannel Pipette 
3-300 µL, 8 channels 
Thermo Fisher Scientific  
4661030N 
Finnpipette F1 Variable Volume Single-
Channel Pipette 
- 0.2-2 µL 
- 0.5-5 µL 
- 1-10 µL 
- 2-20 µL 
- 10-100 µL 
- 20-200 µL 
- 100-1000 µL 
Thermo Fisher Scientific   
 
4641020N 
4641010N 
4641030N 
4641050N 
4641070N 
4641080N 
4641100N 
FLOWMITM Cell Strainers, 40 uM SP Scienceware  136800040 
Flow – tube  Corning Science  352063 
Live/dead Fixable Yellow Dead Cell Stain Kit Life Technologies  L34959 
LS Columns Miltenyi Biotec 130-042-401 
MACSxpress Separator Miltenyi Biotec 130-098-308 
MACSxpress Whole Blood Treg Isolation Kit, 
human 
Miltenyi Biotec 130-109-557 
MicroAmp 8-Cap Strip Applied Biosystems N8010535 
MicroAmp Optical Adhesive Film Applied Biosystems 4311971 
MicroAmp 8-Tube Strip (0.2 mL) Applied Biosystems N8010580 
MidiMACS separator Miltenyi Biotec 130-042-302 
MS Columns  Miltenyi Biotec 130-042-201 
Nitrile Medical Examination Gloves M Abena 290498 
Pasteur pipette  VWR VWRI612-1683 
PAXgene Blood RNA Kit Qiagen 762174 
PAXgene Blood RNA Tubes Qiagen 762165 
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Pipetboy acu 2 Pipette Controller Integra Biosciences  - 
QIAshredder (250) Qiagen 79656 
RNase-free Elution Tubes Thermo Fisher Scientific AM12480 
RNeasy Plus Micro Kit (50) Qiagen 74034 
RNA Pico Chips Agilent Technologies 5067-1513 
RT2 First Strand Kit Qiagen 330401 
RT2 ProfilerTM PCR Array Human T Cell 
Anergy & Immune Tolerance  
Qiagen 330231 
Safe-LockTubes 0.5 mL  Agilent 5065-9940 
Safe-Lock Tubes 1.5 mL, yellow Eppendorf AG 0030 120.159 
Scepter Sensors 40 µm Millipore Corporation PHCC40050 
Serological Pipet 25 mL Falcon  P8250 
Sterile Disposable Plastic Pipettes 10 mL Sterilin  47510 
SuperScript III First-Strand Synthesis System 
for RT-PCR 
Invitrogen/Thermo Fisher 
Scientific 
18080-051 
VWR Reagent Reservoirs  VWR 89094-680 
Zellkultur Testplatten 96U  TPP Techno Plastic Products 
AG 
92697 
 
Table 3: Instruments  
Instrument Producer Catalog number 
ABI Prism 7900 HT Sequence Detection 
System and SDS Enterprise Database 
Applied Biosystems/Thermo 
Fisher Scientific  
- 
Agilent 2100 Bioanalyzer Agilent Technologies G2939BA 
BD LSRFortessa  BD Biosciences  - 
Centrifuge 5810 Eppendorf AG 5810000017 
GeneAmp PCR System 9700 Applied Biosystems/Thermo 
Fisher Scientific 
- 
Heraeus FRESCO 21 Centrifuge Thermo Fisher Scientific 75002555 
Heraeus MULTIFUGE 3SR+ Centrifuge Thermo Fisher Scientific  - 
IKA VORTEX 1 IKA 0004047700 
Incubating Mini Shaker  VWR 12620-942 
Milli-Q IQ 7003/05/10/15 Water Purification 
System 
Merck - 
MiniSpin centrifuge Eppendorf 5452000018 
NanoDrop ND-1000 UV-Vis 
Spectrophotometer 
Thermo Fisher Scientific - 
Scepter Handheld Automated Cell Counter Millipore Corporation PHCC00000 
SpectraMax Plus 384 Spectrophotometer Molecular Devises LLC - 
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Thermomixer compact Eppendorf/Sigma-Aldrich - 
Veriti 96 well Thermal Cycler Applied Biosystems/Thermo 
Fisher 
4375786 
 
Table 4: Software 
Software Producer 
2100 Expert 2.6 Agilent Technologies 
BD FACSDiva BD Biosciences 
FlowJo 10.4 FlowJo, LLC 
GraphPad Prism 8 GraphPad Software 
Microsoft Excel 2016 Microsoft 
ND-1000 3.8 Thermo Fischer 
SDS 2.3 Applied Biosystems 
SoftMax Pro Molecular Devices 
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3. Methods  
3.1. Ethical considerations and the ROAS registry  
The project has approval from the regional committees for medical and health research ethics 
(REK), with REK-numbers 2013/1504 and 2018/1417. All patients and healthy controls have 
provided informed written consent to donate blood to research. The patients are members of 
the registry for organ specific autoimmune diseases (ROAS), while healthy controls were 
recruited from blood donors at Haukeland University Hospital. The registry is a part of the 
section for endocrinology at Haukeland University Hospital (129) and has grown to be one of 
the world’s largest through collaboration with hospitals and labs world-wide (130). ROAS was 
established in 1996 and is a national registry with information from 819 patients with AAD, 
313 patients with hypoparathyroidism and 43 patients with APS-1 (data from 2018) (131) and 
also include a biobank with serum and blood samples. New patient samples are obtained during 
the patients’ yearly follow-up with a specialist in endocrinology.  
 
3.2. Experimental pipeline 
All the methods used in this project are described in the following sections. The flow chart 
below (Fig. 8) gives an overview of the experimental pipeline, which is divided into two parts. 
Part one (Fig. 8 top) involves examining gene expression in the T-cell signalling pathway in 
non-activated cells by quantitative polymerase chain reaction (qPCR). The second part (Fig. 8 
bottom) uses cell culture, enzyme-linked immunosorbent assay (ELISA) and flow cytometry to 
examine the effect of abatacept on T-cells, and qPCR to look at differences in gene expression 
in the T-cell signalling pathway in cells treated or not treated with abatacept. All samples used 
in part two (Fig. 8 bottom) are divided into the following groups 
 
 Patient no drug 
 Patient drug 
 Control no drug 
 Control drug 
 
where “no drug” means no addition of abatacept, while “drug” means that the sample is treated 
with abatacept. This applies to all results, with the exception of qPCR on non-activated cells 
(section 4.3). 
 
 28 
 
Figure 8: Experimental pipeline. The upper part of the figure describes part 1 which involves examining differences in gene 
expression between patients with AAD and healthy controls. The bottom part of the figure describes part 2, which involves 
examining cell protein expression and the effect of abatacept on T-cells in patients with AAD. 
 
3.3. Patients and controls 
AAD patients 1-5 (3 males, 2 females, age range 25-61, mean age 41.6) and healthy controls 
1-5 (3 males, 2 females, age range 28-54, mean age 40.0) were included in the cell culture and 
subsequent analysis by flow cytometry, ELISA and qPCR. RNA from APS-1 patients 6-11 (3 
male, 3 female, age range 22-50, mean age 36.17 years, all had Addison’s disease), AAD patient 
12 (female, age unknown) and healthy controls 6-12 (3 male, 4 female, age unknown) were 
used in the qPCR experiment from resting cells. Additional data on patients 1-12 and controls 
1-5 can be found in Appendix I. For controls 6-12 the only available data was that they were 
age- and sex-matched with patients 6-12.     
 
3.4. Choice of methods  
Flow cytometry is one of the central techniques in this study. Here, lymphocytes derived by 
isolation of PBMC are stained with fluorochrome-conjugated antibodies, specific for the 
surface- and intracellular T-cell and Treg markers of interest, to examine cell protein 
expression. When the fluorochromes passes through the laser beam in the flow cytometer, it 
will absorb light at one wavelength, before being excited to a higher level of energy (132). The 
fluorochromes will almost immediately fall back to the ground state, resulting in fluorescence 
and the emittance of light at a different wavelength, creating a fluorescent signal measured by 
the flow cytometer (132). Filters in the instrument will take up the emitted light, thus permitting 
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distinct wavelengths to pass through (132). Flow cytometry also enables us to investigate how 
the cells scatter light. There are two possible scattering directions, forward (FCS) and side 
(SSC); FCS will give information about cell size (increasing with larger cells), while SSC will 
give information about cell granularity and complexity (increasing with higher complexity) 
(132).  
 
qPCR was used to examine expression of selected genes in the T-cell signalling pathway in 
non-activated cells and in activated cells, treated or untreated with abatacept. Being a 
quantitative method, qPCR can determine the amount of cDNA present, which again directly 
represent the mRNA level in the specimen, and provides opportunities to further normalize the 
data and calculate fold change values by the ∆∆𝐶!-method (133-135), which is described in 
section 3.7. This project involves the use of two different chemistry bases for qPCR; TaqMan 
and SYBR Green. With TaqMan it is necessary to have a probe with a fluorescent reporter dye 
on the 3’ end and a quencher attached to the 5’ end, in addition to a pair of primers (133, 135). 
During the DNA amplification process, cleavage of the probe takes place as a result of the 5’-
nuclease activity of the TaqMan polymerase enzyme, which leads to the reporter being 
separated from the quencher, followed by the generation of a fluorescent signal, detected by the 
qPCR-instrument (133, 135, 136). SYBR Green requires a fluorescent dye that has the ability 
to bind the double stranded DNA qPCR product, giving rise to a fluorescent signal detected by 
the instrument (133, 135).  
 
A sandwich ELISA was here applied to detect secretion of INF-g by activated cells treated or 
not treated with abatacept. The principle is to first coat a plate with an antibody specific for the 
antigen/antibody of interest, in this case a mouse antibody specific for human INF-g (7, 137). 
The addition of standard solutions and, in this case, patient/control samples will enforce binding 
of INF-g to the immobilized capture antibody, and an antibody-antigen-antibody “sandwich” is 
generated by the further addition of INF-g detection antibody (137). Wells containing cells 
producing INF-g will change colour to blue when avidin-horseradish peroxidase (HRP) and 
3,3’,5,5’-tetramethylbenzidine (TMB) substrate solutions are added (137). The intensity of the 
blue colour is proportional to the concentration of INF-g present in the unknown samples, and 
the addition of stop solution will turn the colour of the solutions to yellow (137), before being 
read by the SpectraMax Plus 384 spectrophotometer, at wavelength 450 nm.  
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3.5. Isolation of PBMC 
PBMC was isolated from five healthy controls and five AAD patients. In short, a blood sample 
in a BD vacutainer cell preparation tube (CPT), was centrifuged at 1800 G at 20°C for 15 
minutes. The PBMC layer was pipetted out directly and transferred to a 15 mL Falcon tube and 
washed with phosphate-buffered saline (PBS). Next followed centrifugation at 300 G at 20°C 
for 15 minutes; the supernatant was removed. The pellet was resuspended in PBS and the cells 
were counted by Scepter handheld automated cell counter. The cells were then centrifuged at 
300 G at 20°C for 10 minutes, and the pellet was resuspended in 250 µL AB human serum. A 
solution containing human AB serum and dimethyl sulfoxide (DMSO) was made in a 1:4 ratio, 
and 250 µL was added to the resuspended cells. The cells were transferred to a cryo vial, and 
stored in room temperature for 15 minutes, before being transferred to a cell freezing container 
and stored at  -80°C for two days and further at -150°C until use.  
 
3.6. Isolation of RNA from whole blood and profiling of gene expression related to 
immune tolerance and T-cell anergy 
Blood from six APS-1 patients (all with Addison’s disease), one AAD patient and seven healthy 
controls was drawn from the donor directly into PAXgene Blood RNA Tubes and RNA was 
obtained by using the PAXgene Blood RNA Kit (Qiagen) according to the manufacturer’s 
protocol. The RNA was further transcribed to complementary DNA (cDNA) by the Qiagen RT2 
First Strand Kit. The cDNA was next prepared for qPCR by the Qiagen RT2 Profiler PCR Array 
Human T Cell Anergy & Immune Tolerance Kit, both according to the manufacturer’s protocol. 
In short, cDNA was synthesised from RNA by making a genomic DNA elimination mix, 
followed by incubation at 42°C for one minute and placement on ice. Next, the reverse 
transcriptase mix was prepared and added to the cDNA elimination mix, followed by incubation 
at 42°C for 15 minutes, before the reaction was stopped with a new incubation at 95°C for five 
minutes. The RT2 SYBR Green ROX qPCR Mastermix was prepared and added to the cDNA, 
before being transferred to a 384-well plate in a 4 x 96 PCR array. Samples were run for 40 
cycles on the ABI Prism 7900 HT (table 5), using the SDS 2.3 software.  
 
 
 
 
 
 31 
Table 5: Program used to run qPCR on ABI Prism 7900HT. 
Stage Temperature Time  
1 50°C 2 minutes 
2 95°C 10 minutes 
 
3  
95°C 15 seconds 
60°C 1 minute 
 
The plate used includes 84 different genes in the immune tolerance and anergy pathway, in 
addition to six housekeeping genes, one genomic DNA control, three empty wells and six 
RT/PCR controls in a 4 x 96 array format (138). All genes involved in the analysis can be found 
in appendix II. The fold change was calculated by the use of the ∆∆𝐶!-method in Excel. When 
using the ∆∆𝐶!-method, the Ct-values obtained from the qPCR-instrument were first normalized 
in reference to an endogenous control, usually a housekeeping gene, to obtain a ∆𝐶!-value 
(134). The data were further normalized relative to a calibrator, which gives a ∆∆𝐶!-value, and 
2"∆∆$! further gives the fold change (134). In this case, the mean of housekeeping genes was 
used as reference, while the mean of healthy controls was used as calibrators.  
 
3.7. Cell culture and flow cytometry 
T-cells from five AAD patients and five healthy controls were activated and prepared for flow 
cytometry according to the following protocol. 
 
Coating with anti-CD3 antibody  
Anti-CD3 antibody was diluted to a concentration of 1 µg/mL in sterile PBS and 50 µL was 
added to the wells of a 96-well plate. The plate was incubated at 37°C and 5% CO2 for two 
hours or at 4°C overnight. The wells were washed with 180 µL PBS three times, before 100 µL 
cell suspension was added to the wells. 
 
Preparation of cell medium and carboxy fluorescein diacetate succinimidyl ester (CFSE) 
solution  
Cell medium was supplemented with 50 mL fetal bovine serum (FBS), 20000 𝜇g/mL penicillin-
streptomycin and 200 mM L-glutamine. CFSE solution was prepared by using the Invitrogen 
CFSE Cell Proliferation Kit, to a concentration of 10 µM.  
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Removal of dead cells  
The cells were added to 10 mL warm medium and centrifuged at 300 G for 10 minutes, before 
the Miltenyi Biotech dead cell removal kit was used according to the manufacturer’s protocol. 
The cells were counted using a Scepter handheld automated cell counter and further washed 
with medium at 300 G for 10 minutes.  
 
Activation and functional characterization of the cells  
Cells were resuspended in 1 mL warm PBS, 1 mL PBS-CFSE solution was added and the 
solution was incubated at 37°C for 10 minutes. Next, 2 mL cold PBS was added, followed by 
a five minute incubation on ice. Medium was added to 15 mL, before centrifugation at 300 G 
for 10 minutes. The pellet was then resuspended in warm medium to two million cells. IL2 was 
added to the cell suspension in a 2 µL/mL concentration.   
 
Human CTLA4-Ig (ordered from Chimerigen/Nordic BioSite and here referred to as abatacept) 
was reconstituted to 100 µg/mL in 1 mL sterile PBS and stored in aliquots of 250 µL at -20°C 
until use. A dilution series was made to determine the concentration of abatacept to be used in 
further analysis. Abatacept was prepared in spanning concentrations between 0.65 and 20 
µg/mL diluted in medium. Further, 100 µL cell suspension was transferred to the coated plate, 
together with 100 µL abatacept in given concentrations, giving a total volume of 200 µL in 
each well. In minimum two samples, for both patients and controls, the drug was replaced by 
100 µL medium. Finally, the plate was incubated at 37°C and 5% CO2 for five days. After three 
days the cells were split by transferring 100 µL from each well to a new plate and added 100 
µL medium. After five days the supernatant from each well was harvested and collected in 
Eppendorf tubes, two wells were saved for RNA isolation, while the remaining cells were 
prepared for flow cytometry.   
 
Preparation for flow cytometry 
Lymphocytes derived by isolation of PBMC and cultured for five days were stained with 
fluorochrome-conjugated antibodies specific for the surface- and intracellular markers of 
interest (table 6) and analysed by flow cytometry. The panel has been validated by Heimli in a 
2018 master thesis project (139) and consists of surface- and intracellular markers for different 
subpopulations of T-cells, with specific emphasis on Tregs, based on work by Santegoets et al. 
(65).     
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Table 6: Panel for flow cytometry including targets, dilution factors, excitation and filter 
for emittance.  
Target Fluoro-
chrome 
Dilution 
factor 
Excitation [nm] Filter for emittance 
CD3 V500 1:20 407 670/30 band pass 
CD4 Alexa  
Fluor 700 
1:160 640 730/45 band pass 
CD8 PerCP- 
Cy5.5 
1:20 488 695/40 band pass 
CD25/IL-2RA PE-Cy7 1:40 561 780/60 band pass 
CD45RA APC-H7 1:80 640 780/60 band pass 
CD152/CTLA4 BV421 1:20 407 450/50 band pass 
CD39/ENTPD-1 PE 1:500 561 582/15 band pass 
CD31/PECAM-1 BV785 1:160 407 780/60 band pass 
CD304/Neuropilin-1 BV650 1:80 407 670/30 band pass 
FoxP3 PE-CF594 1:10 561 610/20 band pass 
Helios/IKZF2 APC 1:40 640 670/14 band pass 
Dead cell stain Q-dot585 1:1000 407 585/42 band pass 
CFSE FITC - 488 530/30 band pass 
 
The cell suspensions were prepared for flow cytometry, according to the following protocol; 
The cells were transferred from the plate into flow tubes before centrifugation at 350 G and 4°C 
for 10 minutes. The supernatant was removed and stored at -80°C, until ELISA analysis, and 
the remaining pellet was resuspended in 1 mL PBS. Dead cell stain was dissolved in 50 µL 
DMSO and 1 µL was transferred to the samples, before incubation in the dark at room 
temperature for 20 minutes. Next followed washing with 1 mL PBS with 0.5% BSA and 
centrifugation at 350 G and 4°C for 10 minutes. Supernatant was then removed, and the pellet 
resuspended in the remaining buffer. Further, 2 µL 0.5 mg/mL Fc-block was added, followed 
by incubation in the dark at room temperature for 20 minutes, before the cells were washed as 
previously described.  
 
A mastermix of the cell surface markers was made using anti- CD3, CD4, CD8, CD25, 
CD45RA, CD152, CD39, CD31 and CD304, and added to the samples, and incubated in the 
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dark at 4°C for 20 minutes, followed by a washing step. Anti-human FoxP3 staining kit for 
intracellular staining (Invitrogen) was used for fixation and permeabilization and 1 mL 
fixation/permeabilization buffer was added before incubation overnight at 4°C. The 
permeabilization process was completed by washing with 2 mL 1X permeabilization buffer and 
centrifugation at 500 G and 20°C for five minutes. The cells were then resuspended in the 
remaining buffer. FOXP3 and Helios were added according to the dilution factors in table 7. 
The samples were incubated at 4°C for one hour. Next followed washing with 2 mL 1X 
permeabilization buffer and centrifugation at 500 G and 20°C for five minutes. The cells were 
then resuspended in the remaining buffer and the volume was increased by adding 250 µL 1X 
permeabilization buffer before analysation on the BD LSRFortessa flow cytometer. Further 
data-analysis was done using the FlowJo 10.4 software.  
 
3.8. Isolation of RNA from activated cells and qPCR on activated cells, treated or not 
treated with abatacept 
To isolate RNA from activated cells, treated or untreated with abatacept, from five AAD 
patients and five healthy controls, the RNeasy Plus Micro Kit (Qiagen) was used following the 
manufacturer’s protocol. First, cells from PBMC were resuspended in RLT buffer and run 
through a QIAshredder spin column, before being transferred to a genomic DNA elimination 
column. One volume 70% ethanol was added to the eluted fraction, followed by transfer to a 
RNeasy MinElute spin column. In the following steps, the column was washed with 700 µL 
RW1 buffer, 500 µL RPE buffer and 500 µL 80 % ethanol. To elute the RNA, 14 µL DEPC-
water was added to the column. The last step included a double elution, where the water was 
run twice through the column. The concentration of RNA in each sample was measured on a 
NanoDrop ND-1000 spectrophotometer. According to the manufacturer’s protocol, the Agilent 
RNA 6000 Pico Kit and an Agilent 2100 Bioanalyzer was used to examine the quality of the 
isolated RNA. The 2100 Expert Software was used for analysis and provided RNA integrity 
numbers (RIN). The samples were stored at -80°C until use.    
 
Cells from five AAD patients and five controls activated with IL2, with or without the addition 
of abatacept, and grown in culture for five days were used for RNA extraction, as described 
above, and subsequent cDNA synthesis by the Invitrogen SuperScript III First-Strand Synthesis 
System for RT-PCR. Genes were chosen based on results from the qPCR on non-activated cells 
from patients suffering from APS-1 (section 3.7). For each sample a mastermix for first-strand 
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synthesis containing 0.35 µL random hexamers, 0.35 µL oligo dT20 primer, 0.35 µL 10 mM 
dNTPs and 0.5 µL DEPC water was made and 1.5 µL was added to PCR-tubes. Next, 5 µL 
RNA was then added to the tubes and mixed by pipetting. The samples were incubated on the 
GeneAmp PCR System 9700 at 65°C for five minutes. cDNA was synthesized by making a 
mastermix containing 1 µL 10X RT buffer, 2 µL 25 mM MgCl2, 1 µL 0.1 M DTT, 0.5 µL 
RNase out, 0.5 µL 200 U/µL SuperScript III RT and 1.5 µL DEPC water, and 6.5 µL was added 
to each sample, followed by incubation on the GeneAmp PCR System 9700 (table 7). 
 
Table 7: Program run on GeneAmp PCR system 9700 to synthesize cDNA.  
Stage Temperature Time 
1 25°C 5 minutes 
2 50°C 60 minutes 
3 55°C 15 minutes 
4 70°C 15 minutes 
5 4°C Storage 
 
Next, the cDNA was diluted 50:50 with milli-Q water. A mastermix was made for each gene 
of interest, containing 1.65 µL 20X TaqMan probe/primer mix (CTLA4, Fas Ligand Gene 
(FASLG), inducible T-cell co-stimulator (ICOS), JUN), 1.65 µL 20X housekeeping gene 
(B2M), 16.5 µL 2X TaqMan Gene Expression Mastermix and 9.35 µL DEPC water. Further, 
28 µL of the mastermix was added to a 96-well plate and five µL cDNA was added to each well 
on the plate and mixed by pipetting. Each well on the 96-well plate was pipetted in triplicates, 
adding 10 µL sample solution, to wells of a 384-well plate. The plate was centrifuged at 1000 
rpm for two minutes and 40 cycles were run on the ABI Prism 7900HT, according to the same 
program as shown in table 5.  
 
The SDS 2.3 software provided Ct -values and further analysis was done in Excel by using the 
∆∆𝐶!- method, as described in section 3.7. Normalized gene expression was calculated by 2"∆$! 
(134). The housekeeping gene B2M was used as endogenous control, while the non-treated 
sample in each pair (patient no drug/patient drug, control no drug/control drug) was used as the 
calibrator. For the no drug samples ∆∆𝐶! equals zero and the fold change becomes one, and the 
fold change values for the drug samples will indicate an up- or downregulation in gene 
expression in reference to the no drug samples for both patients and controls (134).  
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3.9. ELISA  
Supernatant from cells grown in culture were saved and used to run ELISA to detect INF-g by 
the ELISA MAX Deluxe Set Human IFN-g (BioLegend), according to the manufacturers 
protocol. A 96-well plate was coated with capture antibody solution and incubated at 4°C 
overnight. Next, the plate was washed four times with 300 µL wash buffer, which counts for 
all the following wash steps. Further, 1X assay diluent A was added to the wells before 
incubation on a plate shaker at 500 rpm for one hour. This was followed by a new wash step. 
Samples were diluted 1:25 and 1:100, and standards and samples were added to the wells in 
triplicates. The plate was next incubated with shaking at 500 rpm for two hours, before washing. 
Detection antibody was added to the wells, followed by incubation on the plate shaker at 500 
rpm for one hour. The plate was washed, before Avidin-HRP solution was added. The plate 
was then incubated with shaking at 500 rpm for 30 minutes. This was followed by a five round 
wash step. Each wash was soaked on the plate for 30 seconds, before TBM substrate solution 
was added. This was followed by incubation in the dark for 20 minutes, before the addition of 
stop solution. The absorbance was measured at 450 nm by using the SpectraMax Plus 384 
Spectrophotometer. Standard curve and INF-g concentrations in each sample were acquired by 
the use of the SoftMax Pro software. The software also provided adjusted concentration values, 
taking the dilutions into consideration. The sensitivity of the ELISA kit was 4 pg/mL.  
 
3.10. Statistical analysis 
For the qPCR on non-activated cells (section 3.7), statistical analysis was done in a “default” 
spreadsheet (Excel) made by the manufacturer, using multiple t-tests. Statistical analysis for the 
remaining experiments was done using GraphPad Prism 8. When examining differences within 
the patient no drug/drug population and within the control no drug/drug population a paired 
parametric t-test was used. In order to compare patient and control samples, treated or not with 
abatacept, an unpaired non-parametric t-test was performed (Mann-Whitney test). For all 
statistical analyses, unless otherwise described in the text, a significant result was characterized 
by a p-value less than 0.05. The mean is represented in the plots even though a non-parametric 
approach has been chosen in some of the statistical calculations. When examining differences 
between patient and control groups, data are presented as mean percent point ± standard 
deviation and mean proliferation index ± standard deviation for the flow cytometry data, and 
mean concentration [pg/mL] ± standard deviation for the ELISA data.  
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4. Results 
4.1. Isolation of PBMC 
From isolation of PBMC a concentration of (0.500 – 9) x 105 cells/mL was obtained from each 
subject. Five age- and sex-matched controls were selected for use in cell culture, flow 
cytometry, ELISA and qPCR. Number of cells obtained in each sample used in isolation of 
PBMC can be found in Appendix III. 
 
4.2. Isolation of RNA from activated cells treated or not treated with abatacept  
RNA from five AAD patients and five age- and sex-matched healthy controls was isolated from 
activated cells, treated or untreated with abatacept, and grown in culture for five days. We 
obtained RNA concentrations ranging from 0.85 to 61.83 ng/mL. In general, the obtained 
concentrations of RNA from each sample were low. An example of an output from the Agilent 
2100 Bioanalyzer is shown in Fig. 9. This sample is from control 5 with and without treatment. 
Two clear bands, representing 18S and 28S RNA, were obtained and observed on the gel (Fig. 
9 (a)). The nucleotide number versus fluorescence graph gave two well-defined peaks, 
representing the 18S and 28S RNA, respectively (Fig. 9 (b)). RIN values of 9.10 (control 5 no 
drug) and 9.20 (control 5 drug) was here considered indicative of high-quality RNA (140). The 
isolated RNA was further used in qPCR analysis of activated cells, despite low concentrations 
and/or poor quality. Concentration- and RIN-values for patients and controls 1-5 can be found 
in Appendix IV. Due to low sample volume, it was not possible to obtain RIN-values for all 
samples (Appendix IV). 
 
Figure 9: RNA quality result from the Agilent 2100 Bioanalyzer, here exemplified by samples from control 5. (a) The 
gel picture showed two easily distinguishable bands, representing 18S and 28S RNA, respectively. (b) The nucleotide number 
versus fluorescence graph gave two well-defined peaks. The first one appearing represents 18S RNA, while the second 
represents 28S RNA. RNA integrity numbers of 9.10 (control no drug) and 9.20 (control drug) indicated RNA of good quality. 
All RNA samples were used in the qPCR experiment in activated cells, treated or not treated with abatacept, despite low 
concentration and/or poor quality. 
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4.3. RNA expression profiling of genes related to immune tolerance and T cell anergy 
In order to identify genes within the T-cell tolerance pathway, including CTLA4, which possibly 
differed between patients and controls, we utilized a commercial qPCR assay including 84 
relevant genes. RNA was obtained from the ROAS registry, all with RIN values indicating high 
quality RNA (not shown), from seven AAD patients and seven age- and sex-matched controls 
were analysed for the expression of 84 genes. Genes with deviant expression between patients 
and controls was then further analysed in activated cells, treated or not, with a CTLA4 agonist 
(abatacept) in downstream experiments. 
 
Results from the analysis of RT2 real time profiling data are shown in Fig. 10. Of the 84 genes, 
52 amplified in all 14 samples (seven patients and seven controls), while 31 genes amplified in 
between 1 and 13 samples, with varying numbers of patients and controls involved. One gene 
did not give output for all seven control samples, only for one patient sample (IL17A), indicating 
very low expression. All wells passed the control steps, except for sample 1 in the control group, 
where there was a question about the efficacy of the reverse transcriptase process, but the 
sample was still included. Eleven genes are presented (Fig. 10) and were selected based on 
either a fold change value between patient and control larger than 3 and/or a p-value less than 
0.05. Data for the remaining genes can be found in appendix II.   
 
The instrument was set to run 40 cycles, and products appearing after this were considered 
undetermined due to low expression. These values were removed from the dataset and not taken 
into consideration. This leads to a lowered number of replicates, meaning that the number of 
patients and controls did not always match. The “default” spread-sheet used to analyse the data 
(from the manufacturer) had a cut-off value set as 35, this was changed to 40 by us, thus taking 
into consideration the values between 35 and 40. If there were less than three replicates from 
each group, statistical analysis was not done, but the fold change was still used as an indicator 
for differences. Taking ICOS as an example, a positive upregulation of 26.91 was observed 
(Fig. 10), but there was no obtained p-value. This was because there were only two controls left 
after removing undetermined and low-expression results. The fold change values (Fig. 10) 
reflects a positive or negative regulation compared to the patient group. A positive value 
indicated a higher expression in patient versus control, while a negative value indicated lower 
expression in patients versus controls. To correct for multiple testing in this experiment (since 
we were testing 84 genes in the same setup) the threshold for a significant result was decreased 
to 0.01. This implied that the change seen between patient and control for FASLG (Fig. 10) was 
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not considered statistically significant.  
 
Six of the genes presented (LTA, JAK3, IL13, IL10, IFNG, ICOS) (Fig. 10) had an overall high 
threshold value, meaning that the expression was low for both patient and control samples, and 
the p-value was greater than 0.01, i.e. there was no statistical differences between the groups. 
In general, the expression of genes in both patients and controls were low, as many signals 
appeared late in the qPCR setup (high Ct value) (not shown).  
 
We chose four genes on the basis of these qPCR results in resting cells to investigate 
mechanisms in response to abatacept in downstream applications for activated cells: FASLG 
(because it was close to obtaining significant adjusted p-value), ICOS and JUN (with relatively 
large fold change values between the groups) and CTLA4 (because of its relevance for 
abatacept). 
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Figure 10: Results from RT2 real time profiling for 11 of the 84 genes. The number of matched patients and controls for 
each gene are presented under the graphs. Fold change values are presented for all genes. A negative value means that the 
expression was higher in the control group, while a positive value means that the expression was higher in the patient group. 
The box represents the mean fold change value, while the red line indicates standard deviation. Statistical analyses was 
performed in a spreadsheet provided by Qiagen, using multiple t-tests.   
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4.4. qPCR on activated cells, treated or untreated with abatacept  
The isolated RNA samples from activated cells, with or without abatacept, from five AAD 
patients and five healthy controls were further investigated for gene expression of selected 
genes. A TaqMan qPCR assay was performed including four genes (CTLA4, FASLG, ICOS, 
JUN) that were chosen based on results from the qPCR done on non-activated cells from APS-
1 patients, an AAD patient and healthy controls (Fig. 10, section 4.3). The qPCR-instrument 
was set to run 40 cycles and signals appearing after these cycles were excluded due to very low 
or non-existing expression. For control 3, in the analysis of JUN, no Ct-values were obtained, 
and the sample was thus removed. Therefore, five patients and four controls were a part of the 
JUN analysis. When comparing normalized gene expression (2"∆$!) before and after treatment 
with abatacept in patients and controls samples, we found no significant differences for the four 
candidate genes within the two groups (Fig. 11). Indeed, the expression of the selected genes 
were very low, appeared late in the qPCR cycle (not shown) and the results fluctuated greatly 
within the groups and between patients and controls (Fig. 11).  
 
Figure 11: qPCR on activated cells, treated or not, with abatacept; normalized gene expression. (a) CTLA4 patients and 
controls, (b) FASLG patients and controls, (c) ICOS patients and controls and (d) JUN patients and controls. Normalized gene 
expression, given as 2!∆#! makes up the y-axis, and gives the opportunity to compare expression before and after treatment 
with abatacept. Parametric paired t-tests did not give significant differences between patients no drug/drug and controls no 
drug/drug. There were no clear trends when looking at the results, as gene expression both increase and decrease when 
comparing the no drug and drug samples for individual subjects. The overall gene expression for all four genes, for both 
patients and controls, were low.  
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Fold change values were calculated as described previously (section 3.7) and presented in Fig. 
12. Since the no drug samples for both patients and controls were used as calibrators (section 
3.9) these fold change values equals one, indicated by a horizontal line (Fig. 12). Fold change 
values were thus plotted for the patient drug and control drug groups and provided an indication 
of up- or downregulation for the samples treated with abatacept in relation to the samples with 
fold change values of one (not treated with abatacept). For CTLA4, samples from patient 1, 4 
and 5 (treated with abatacept), showed a slight downregulation, while patient 2 had a higher 
expression (Fig. 12). Patient 3 did not show signs of up- or downregulation (Fig. 12). The 
control samples were all under the horizontal line for CTLA4, which could be an indication of 
a lower expression in the samples treated with abatacept, compared to the non-treated samples. 
Statistical analysis looking at differences between patient drug and control drug gave no 
significant differences. All genes in the patient population contained a sample with higher 
expression than the remaining samples, and for FASLG, ICOS and JUN this was the same 
sample, patient 5.  
 
 
Figure 12: qPCR on activated cells treated abatacept; fold change values for patient and control samples treated with 
abatacept. (a) CTLA4, (b) FASLG, (c) ICOS and (d) JUN. Fold change values for the no drug samples equal one, as they were 
used as calibrators, which is marked by the horizontal line. Statistical analyses (non-parametric unpaired t-test) performed 
between patients and controls treated with abatacept did not give any significant differences. These results indicate no change 
in gene expression after treatment with abatacept for neither patients nor controls, and that abatacept does not affect the 
expression of these genes. The boxes represents the mean, while the error bars show the standard deviation.   
 
4.5. Cell culture and flow cytometry 
The effect of abatacept on T-cells was examined in five patients with AAD and five age- and 
sex-matched healthy controls by cell culture and flow cytometry. Based on preliminary titration 
data, an abatacept concentration of 20 𝜇g/mL was chosen for use in the cell based assay. After 
being activated in cell culture for five days, the cells were analysed by flow cytometry, which 
was used to analyse at cell protein expression.   
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4.5.1. Gating strategy 
An example of the gating strategies used is shown in figures 13-15, all showing control 1 with 
no drug. The gating strategy was the same for all remaining samples. First, gating was set for 
all cells present in the given sample, using an FSC versus SSC plot. Next, it was gated for single 
cells, using an FSC-A versus FSC-H plot. From single cells the gating was set to live cells. To 
make sure that we were only looking at T-cells, it was gated for CD3+ cells and further for 
CD4+ and CD25+ FOXP3+ cells (Fig. 13).  
 
Figure 13: Gating strategy I. Lymphocytes, singlets, live, CD3+, CD4+, CD25+ FOXP3+ cells. The first gating included all 
cells present, both live and dead, using an FSC versus SSC plot. Further the gate was set to singlets, using an SSC versus FSC 
plot. The next gating was for live cells, thus making sure that no dead cells were present in the analysis, by the use of an SSC 
versus live/dead marker plot. From the live population it was gated for CD3+ cells, ensuring the presence of T-lymphocytes. 
Further gating involved separating CD4+ cells from CD8+ cells, before gating on CD25+FOXP3+ cells.  
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Within the CD4+ population it was gated for different T-cell markers (Fig. 14). These markers 
were CD25, CD45RA and CTLA4. Expression of CD45RA, CTLA4 and other markers within 
CD4+ population did not give significant results within and between patients and controls, and 
the results are thus not shown.  
 
 
Figure 14: Gating strategy II. Lymphocytes, singlets, live, CD3+, CD4+ cells expressing (a) CD25+, (b) CD45RA+ and (c) 
CTLA4+. From the CD4+ population it was gated for different T-cell markers of interest. These include, from the top left: 
CD25, CD45RA and CTLA4. 
 
Within the population of CD25+ cells expressing FOXP3, it was gated for markers of T-cells 
and Tregs (CD31, CD39, CD304, CTLA4 and Helios) (Fig. 15).    
 
 
Figure 15: Gating strategy III. Singlets, live, CD3+, CD4+, CD25+, FOXP3+cells expressing (a) CD31, (b) CD39, (c) 
CD304, (d) CTLA4 and (e) Helios. Within the FOXP3 positive cell population the gating is again set to intra- and 
extracellular Treg markers, making sure that one has managed to characterize the wanted cell population. These 
markers include CD31, CD39, CD304, CTLA4 and Helios. 
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4.5.2. Live cells 
We plated 200000 cells (PBMC) per well and were left with different cell numbers after cell 
harvesting and staining. This was seen in the flow cytometry results, where a difference in the 
fraction of live cells between the samples was observed. The following figure shows one 
representative flow figure for one of the patient samples (patient 5) (Fig. 16 (a)). From the 
diagram in Fig. 16 (b) it is further seen that the overall number of live cells, for both patients 
(no drug: 57.700±25.492, drug: 43.580±25.015) and controls (no drug: 64.360±15.333, drug: 
57.960±11.835) were highest for the samples not treated with abatacept. A statistically 
significant decrease in the fraction of live cells was found within the patient population after 
the addition of abatacept (p-value 0.0018), supporting a trend towards abatacept reducing the 
live cell fraction (Fig. 16 (c)). All control samples, with the exception of control 2 who showed 
a slight increase, had a lower frequency of live cells post-treatment with abatacept, but 
significance was not obtained (p-value 0.1401) (Fig. 16 (d)).  
 
Figure 16: Live cells. (a) Shows an example of what the live fraction might look like. Here, patient 5 is representative for all 
samples. (b) The fraction of live cells within the single positive cell population for both patients and controls. Live cell fractions 
vary from under 20 to over 80 when looking at frequency of parent. The boxes give the mean values, while the error bars 
represents standard deviation. Statistical analysis on differences between the two groups (patients and controls) can be found 
in table 8. (c) Comparison of patient no drug and patient drug samples. A significant p-value of 0.0018 was obtained when 
performing a paired parametric t-test between patients no drug and drug. (d) Comparison of control samples with and without 
abatacept. Statistical significance was not found within the control population (p-value 0.1401) by using a paired parametric 
t-test.   
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4.5.3. Cell survival and proliferation 
We investigated how the cells divide within the CD4+ population, by using the proliferation 
index. Staining the cells with CFSE gave us the opportunity to track the rounds of cell division 
(141), where the proliferation index represents the mean number (142), and was here analyzed 
by FlowJo. We looked for significant differences between the no drug and drug samples for 
both patients and controls. It was observed that the cells had a lower frequency of division when 
treated with abatacept in both groups (Fig. 17). Patient cells were not dividing as frequently 
when drug was added, compared to the no drug samples (Fig. 17 (a)). The exception was patient 
5, where a small increase in proliferation was observed after the addition of drug. Differences 
in proliferation between patients no drug and drug were found to be significant (p-value 
0.0462). Unlike the patient samples, all control samples showed a decreased proliferation index 
when treated with abatacept, but no significance was obtained (p-value 0.1007) (Fig. 17 (b)).  
 
 
Figure 17: Comparison of proliferation indexes within (a) patient and (b) control populations. A measure of cell division 
was given by the proliferation index. The results indicated, with significance (p-value 0.0462), that the patients’ cells had a 
lower frequency of division when treated with abatacept. For the controls, all samples showed a decreased rate of division 
when abatacept had been added, but the difference before and after treatment was not statistically significant, with a p-value 
of 0.1007. P-values were obtained by performing a paired parametric t-test between patients no drug and drug, and between 
controls no drug and drug.  
 
When looking at cell proliferation, the results did not indicate any difference in the division rate 
between patients and controls no drug and drug, even though the patients (no drug: 
1.680±0.277, drug: 1.522±0.247), in average, seemed to have cells dividing at a higher rate 
than the controls (no drug: 1.566±0.353, drug: 1.352±0.218) after the addition of abatacept 
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(Fig. 18 (a) and (b)). No significant differences were found when comparing patients and 
controls no drug (p-value 0.5476), and patients and controls drug (p-value 0.2460) (Fig. 18 (a) 
og (b)). 
 
 
Figure 18: Comparison of proliferation indexes from patients and controls. (a) Patients and controls no drug, and (b) 
Patients and control drug. In average it seemed like the patients had cells with a slightly higher ability to divide after 
treatment, but there was not found significance when looking at differences between the patient and the control groups, both 
with and without the presence of abatacept. To examine differences between patients and controls no drug, and patients and 
controls drug populations, a Mann-Whitney unpaired, non-parametric t-test was used. The boxes represents the mean 
proliferation index and the standard deviation is given by the error bars.  
 
4.5.4. Activated cells 
CD25 was used as a marker for T-cell activation (66) and the gating strategy for CD25 is shown 
in Fig. 19 (a). A flow figure is shown for patient and control 4 no drug and drug (Fig. 19 (a)). 
The fraction of activated cells decreased in the samples with abatacept added compared to the 
no drug samples for both patients and controls (Fig. 19 (b)). Statistical analysis gave significant 
results between patient no drug and patient drug (p-value 0.0425), but not for the controls (p-
value 0.1411). The graph and numbers still gave a clear indication of a lower frequency of 
activated cells after treatment with abatacept, which was the case for all patients and controls, 
and for the patient samples supported by a significant p-value of 0.0425 (Fig. 19 (c)).    
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Figure 19: Frequency of CD4+ cells expressing CD25 (activated cells). (a) Example showing the population of activated 
cells, here represented by patient and control 4 no drug (top) and patient and control 4 drug (bottom) (b) The fraction of 
activated cells within the CD4+ population for both patients and controls are shown, statistical data can be found in table 8. 
The boxes show the mean values of expression, while the standard deviation is represented by the error bars. (c) Comparison 
of patient and control no drug with patient and control drug, respectively. Statistical analysis (paired parametric t-test within 
patient and control populations) gave significant results for the patient population (p-value 0.0425), which was indicative of 
the frequency of activated cells being lower when treated with the drug. Significance was not found for the controls (p-value 
0.1411).  
 
From the cells expressing CD25 (activated cells), we examined the expression of CTLA4 (Fig. 
20). The representative flow figure included (Fig. 20 (a)) is from patient and control 5. The 
results indicated that the patients (no drug: 14.540±22.524, drug: 18.368±19.318, p-value 
0.5487), in average, had a higher fraction of CTLA4 expressing cells after being treated with 
abatacept, compared to the no drug samples and to the controls (no drug: 5.280±3.387, drug: 
10.918±13.452, p-value 0.3605) (Fig. 20 (b)). Statistics performed between patient no 
drug/drug and between controls no drug/drug, did not lead to significance (Fig. 20 (c)).   
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Figure 20: Frequency of CD25+ cell expressing CTLA4. (a) Flow results showing fraction of CD25+cells expressing CTLA4, 
here exemplified by patient and control 5. (b) Overview of all sample parallels from both patients and controls. Mean values 
are represented by the boxes and the standard deviation by the error bars. For statistical analysis see table 8. (c) Comparison 
of CTLA4 frequency within patient and control populations respectively. Statistical analysis (Wilcoxon paired, non-parametric 
t-test within patient and control populations) did not lead to significant p-values, which were high for both patients and controls 
when comparing no drug and drug samples.     
 
We also examined the expression of CD31, CD39, CD304 and Helios in activated cells. A close 
to significant p-value of 0.0625 was obtained for CD31 in the patient population, and for CD39 
a relatively low p-value of 0.0810 was obtained, also for the patient samples (Fig. 21 (a) and 
(b)). No significant results were found for the other markers and a variation in expression, both 
for no drug and drug, was observed (Fig. 21).  
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Figure 21: Expression of different T-cell markers in activated cells. (a) CD31+ cells within CD25+ population patients 
(upper panel) and controls (lower panel). (b) CD39+ cells within CD25+ population patients (upper panel) and controls (lower 
panel). (c) CD304+ cells within CD25+ population patients (upper panel) and controls (lower panel). (d) Helios+ cells within 
CD25+ population patients (upper panel) and controls (lower panel). No significant differences were found between no drug 
and drug for neither patients nor the controls, when performing a paired parametric t-test within the two populations. Near 
significant differences were found for CD31 (patients) and for CD39 (patients), supported by p-values of 0.0625 and 0.0810 
respectively. 
 
4.5.5. Tregs and CTLA4 
From the population of CD4+ cells expressing CD25, it was further gated on cells expressing 
FOXP3, i.e. Tregs (38). The results indicated a decrease in the FOXP3 expressing population 
for patient 1, 3, 5 and 6, while an increase was seen for patient 2 with the addition of drug, when 
compared to the no drug samples (Fig. 22). This was also the case when looking at the control 
samples; there was a decrease in the FOXP3+ cell fraction in the presence of drug for control 2, 
3, 4 and 5, while control 1 showed an increase. A flow figure is included, here represented by 
patient and control 5 (Fig. 22 (a)). Overall, patient samples (no drug: 22.010±21.947, drug: 
19.224±21.643) had a higher fraction of FOXP3 expressing cells than the control samples (no 
drug: 14.562±10.584, drug: 10.552±9.434) (Fig. 22 (b)). There were no differences between 
patient no drug and patient drug (p-value 0.4838), as were the case for the control group (p-
value 0.3489) (Fig. 22 (c)).  
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Figure 22: Fraction of CD4+ CD25+ cells expressing FOXP3 (Tregs). (a) Fraction of CD25 positive cells expressing FOXP3, 
here exemplified by patient 5 no drug (top) and patient 5 drug (bottom). (b) The majority of the samples showed a decrease in 
the frequency of FOXP3 expressing cells when comparing no drug and drug samples for both patients and controls. Mean 
values are presented by the boxes, while the error bars show the standard deviation, for statistical analysis please see table 8. 
(c) For one patient sample (patient 4) and one control sample (control 3) there was an increase in the FOXP3 positive 
population when the sample was treated with abatacept. The results were considered not significant as no p-values less than 
0.05 were obtained. Statistical analysis involved a paired parametric t-test performed between patients no drug and drug, and 
between controls no drug and drug.   
 
Within the FOXP3+ population it was gated for cells expressing CTLA4. Fractions of CTLA4 
expressing cells within the Treg population are shown in Fig. 23, where a flow figure is included 
from patient and control 4 (Fig. 23 (a)). In general, the results indicated that the fraction of 
Tregs expressing CTLA4 was increased when going from no drug to drug for both patients and 
controls (Fig. 23 (b)). The exception was control 4 where a decrease was observed when 
comparing the no drug and drug samples. Statistical analysis gave a significant p-value of 
0.0092 for the patient population, while no significance was found for the control group (p-
value 0.1170), when looking at differences between no drug and drug. All samples from patients 
showed an increased expression of the CTLA4 on Tregs when treated with abatacept, a trend 
that was supported by a relatively low p-value of 0.0092 (Fig. 23 (c)).  
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Figure 23: Fraction of FOXP3+ cells expressing CTLA4. (a) Fraction of FOXP3 positive cells expressing CTLA4, here 
exemplified by patient and control 4 no drug (top) and patient and control 4 drug (bottom). (b) The majority of samples showed 
an in increase in the CTLA4 expressing population after the addition of abatacept, here represented by mean values (boxes) 
and standard deviation (error bars), in addition to the individual values. Statistical analysis can be found in table 8. (c) 
Comparison of patient and control no drug with the samples added drug for all parallels. All samples, except for control 4, 
showed an increase in the fraction of FOXP3 positive cells expressing CTLA4 after abatacept was added. The results were 
considered not significant, as the p-value obtained from paired parametric t-tests between control no drug and drug, was over 
0.05. For the patients, the differences were considered statistically significant, based on a p-value of 0.0092.   
 
Data for the remaining Treg markers (CD31, CD39, CD304, Helios) are shown in Fig. 24. The 
results showed great variation in the fraction of cells expressing the different markers, as it both 
decreases and increases, when comparing cells treated or not treated with abatacept. The 
exception was CD39 (Fig. 24 (b)), where the trend clearly indicated a decrease in protein 
expression from the no drug to the drug population for both patients (p-value 0.0387) and 
controls (p-value 0.0466), a trend supported by significant p-values.  
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Figure 24: Cell expression of different Treg markers within the CD4+CD25+FOXP3+ population. (a) CD31 patients and 
controls, (b) CD39 patients and controls, (c) CD304 patients and controls, and (d) Helios patients and controls. The cells, 
treated or not with abatacept, showed a great variation in the expression of different Treg markers. No significant results were 
obtained, as most p-values were high. Most samples showed both an increase and a decrease in protein expression, when 
looking at both patient and control samples for most markers. CD39 was the exception. For this marker, the graph clearly 
showed a decrease in expression, for both patients and controls, when going from the no drug to the drug population. The 
observed trend is strengthened by significant p-values of 0.0387 and 0.0466 for patients and controls respectively. Paired 
parametric t-tests were performed between patients no drug and drug, and between controls no drug and drug samples, to look 
for significance.  
 
To further examine differences between patients and controls for some of the cell markers, we 
normalized the data by taking the difference between no drug and drug for each subject and 
within each group of patients and controls, respectively. After normalization, statistical 
analyses were performed between patient and controls for proliferation and different 
subpopulations of cells (live cells, activated cells, Tregs and CTLA4 within CD25+ and 
FOXP3+ cells), including Treg markers and CTLA4. No significant p-values were obtained 
(table 8) and thus there was no difference between the two groups.  
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Table 8: Statistics on normalized data between patients and controls.  
Cell population Average difference 
between no drug and drug 
(% point) 
P-value 
Patient Control 
Proliferation 0.16 0.21 0.8889 
Live cells within 
lymphocytes, singlets 
population 
9.1 6.70 0.5476 
CD25+ within CD4+ 
population 
9.76 20.58 0.4206 
CTLA4+ within CD4+ CD25+ 
population 
-3.83 -5.64 0.8413 
FOXP3+ within CD4+ CD25+ 
population 
2.74 3.88 0.5476 
CTLA4+ within CD4+ CD25+ 
FOXP3+ population 
-12.19 -16.52 >0.9999 
CD31+ within CD4+ CD25+ 
FOXP3+ population 
0.98 2.36 0.5476 
CD39+ within CD4+ CD25+ 
FOXP3+ population 
8.36 10.52 0.6905 
CD304+ within CD4+ CD25+ 
FOXP3+ population 
-0.99 -0.47 0.6905 
Helios+ within CD4+ CD25+ 
FOXP3+ population 
-10.69 -8.64 >0.9999 
 
 
4.6. IFN-𝜸 production in cells treated or untreated with abatacept  
A sandwich ELISA was performed on the supernatants from the activated cells, treated or not 
with abatacept, in order to detect expression of IFN-g. The concentration of IFN-g was 
determined by measurement of the absorbance at 450 nm and by the generation of a standard 
curve (Appendix V). IFN-g concentration in each sample, adjusted for dilution factors, was 
provided directly by the software used for analysis. Samples not falling within the range of the 
 55 
standard curve was further diluted and run in a second ELISA assay.  
 
The results indicated that the patients had a higher production of IFN-g (no drug: 18160±31387 
pg/mL, drug: 20155±36651 pg/mL), compared to the control samples (no drug: 7763±12945 
pg/mL, drug: 2030±3432 pg/mL), both with and without the addition of abatacept (Fig. 25). 
For all patient and control samples, except patient 2, the concentration of IFN-g was decreased 
when the cells were treated with abatacept (Fig. 25). It was further observed that patient 2 had 
a very high IFN-g concentration, compared to the other samples (Fig. 25 (a)). This sample was 
not within the range of the standard curve, but it is still presented and considered in statistical 
analysis. Given that the kit used has its limitations in accepted concentration values, the 
concentration of this sample could be even higher than reported here. Patient 5 drug and control 
3 drug also fell outside the range of the standard curve, with no detectable concentration of 
IFN-g and their concentration values were set to zero, and included in the statistical analysis. 
No significance was found when examining differences between no drug and drug within the 
patient (p-value 0.4049) and control (p-value 0.2364) populations respectively.   
 
 
Figure 25: Concentration of IFN-g  in (a) patient and (b) control samples. For the majority of samples, from both patients 
and controls, the concentration of IFN-g decreased when the cells were treated with abatacept. All five control samples had a 
lower concentration of IFN-g when treated with abatacept, but for control 3 no drug the concentration was too low to fit 
within the range of the standard curve. Patient 2 showed a much higher concentration than all other samples  and also gave 
a small increase in concentration with the addition of abatacept. The production of IFN-g seemed to be higher in the patient 
samples, compared to controls. Statistical analysis examining differences within the patient and control samples (paired 
parametric t-tests) did not lead to significance for neither patients (p-value 0.4049) nor controls (p-value 0.2364).  
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Due to the large variation in the concentration of IFN-𝛾, within and between patient and control 
populations, we further normalised the values by using the differences between the no drug and 
drug samples within the patient and control population, but no difference was found between 
groups (p-value 0.4206). Patients had a mean difference in concentration of 4056.83 pg/mL, 
while controls had a mean difference of 7363.59 pg/mL, indicating that the overall amount of 
IFN-g was larger in the no drug population for both patients and controls.  We also compared 
patients and controls no drug, and patients and controls drug, without finding significant 
differences (Fig. 26). All samples were used in the statistical analysis and presented in Fig. 26, 
despite being outside the range of the standard curve.  
 
 
Figure 26: Differences between patients and controls no drug, and patients and controls drug. To search for differences 
between no drug and drug we compared patient and control samples within the two populations. No significant differences 
were discovered, but the patients seemed to have a higher IFN-g concentration both before and after treatment with abatacept, 
compared to the controls. For both patients and controls, the levels of IFN-g were highest without the addition of abatacept. 
Statistical analysis looking at differences between the two populations (Mann Whitney unpaired, non-parametric t-tests), did 
not lead to a significant result. Here, the boxes represent the mean IFN-g concentration values, while the error bars show the 
standard deviation.     
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5. Discussion 
5.1. The effect of abatacept on T-cells in patients with AAD can be screened by the 
method developed  
We aimed to develop a method for in vitro drug screening in AAD patients at the KG Jebsen 
Center for Autoimmune Diseases to search for new treatment options, as these patients suffer 
from, amongst other, lower quality of life due to the unphysiological replacement therapy (126-
128). The assay developed included treating cells from AAD patients and healthy controls with 
abatacept, growing them in cell culture for five days, staining with T-cell and Treg markers, 
and examine cell protein expression by flow cytometry, the production of IFN-g by ELISA and 
transcription of selected genes by qPCR. We observed that the cells were able to divide and 
expand in vitro and results from flow cytometry showed decreased proliferation for the majority 
of samples post-treatment with abatacept. All together, these observations indicated that the 
developed method is suitable for in vitro drug analysis. Even though the assay proved 
successful, it was quite time consuming, raising questions about the efficiency. From start to 
finish it took almost a week to obtain results. Here, we also screened the effect of only one 
possible drug (abatacept) in one autoimmune disease (AAD) and method optimization is 
necessary before large-scale screening could be a possibility.  
 
Our study had some limitations. The effect of abatacept was examined in only five AAD 
patients and five healthy controls, while six APS-1 patients, one AAD patient and seven healthy 
controls were used in qPCR involving non-activated cells, in the search for candidate genes. 
APS-1 patients involved in the study were all suffering from AAD, which is one out of three 
criteria for diagnosis (34), and was also the rationale for including them. The low number of 
patients and controls gave the study a low statistical power and the inclusion of more test 
subjects would have been beneficial. Thus, we have to use caution when interpreting the results 
of the statistical tests used. Patients were chosen to participate without taking the duration of 
AAD into consideration. We do not know if this affected how they respond to abatacept 
treatment, as it has not yet been examined in these patients, but in type 1 diabetes, the effect 
have been studied in patients with recent-onset disease (122, 123). All controls were age- and 
sex-matched with the patients, and we sat an age limit of ±10 years for the controls. Even 
though autoimmune diseases are known to have a higher prevalence in female than in male, the 
prevalence is close to the same for both sexes in AAD (female:male ratio 1.5-3.5:1 ) (103, 143, 
144). Despite this, we still chose to sex-match the controls, thus taking biological differences 
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that could be caused by age and sex into consideration.  
 
We have been working with human biological material and did not have continuous access to 
sample material. PBMC from patients were obtained from the ROAS registry, while PBMC 
from healthy controls were isolated from fresh blood samples obtained from the blood bank at 
Haukeland University Hospital. Both patient and control samples were stored at -150℃ until 
use. It was observed that the number of cells obtained from each sample fluctuated greatly, 
most likely due to biological differences between individuals, as some individuals might have 
a higher/lower white blood cell count than others (145), or it could be due to faults in 
experimental techniques, such as pipetting. To try to improve the number of cells, one 
possibility would have been to use Ficoll-Paque density centrifugation media instead of the 
CPT Vacutainer tubes for PBMC isolation, but a study by Corkum et al. have shown that the 
two methods are equally efficient (146). We had no available information about neither patients 
nor controls at the time of blood testing, except for sex, age and, for the patients, a diagnosis. 
We did not know if the subjects had an ongoing infection or if they were recovering from a 
recent infection, if they were on any medications, or if the blood was drawn fasting. Also, we 
did not have information about the treatment the patients were receiving or what time of day 
the samples were taken. All factors mentioned above could have affected the results (147, 148).  
 
During the experiment, we also experienced problems with cell-loss, which might be caused by 
freezing and thawing of samples and/or several washing and transferring steps, all increasing 
the probability for loss of product (147). In addition, we observed variations between the assays 
run on different days. This was especially seen in the live cell fraction, which decreased by a 
considerable amount from assays 1-2 to assays 3-5, with indications of a larger decrease 
amongst the patients (Fig. 16 (c)). We also saw, in flow cytometry, that some of the populations 
“moved” in the last assays, when compared to the first ones. We do not know why this occurred, 
as all cells were treated equally in sample preparations, cell culture and analysis by flow 
cytometry. The only difference between the assays was how the plate coated with anti-CD3 was 
handled. For assays 1-2 the plate was coated and incubated at 37℃ and 5% CO2 for two hours, 
while for assays 3-5 the plate was coated and sealed one day prior to the experiment, and stored 
at 4℃ overnight. We do not know for certain if this has affected our results, but as the plate was 
properly sealed, we believe that a possible effect was minimal. We chose to let the cells grow 
and expand in culture for five days, in order to examine cell proliferation. The cells were treated 
with abatacept once at day one and after this treatment was discontinued. At day three the cells 
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were split and given more medium, thus ensuring that they were given enough room to continue 
expanding. We questioned if abatacept should have been dosed more than once during the five 
days, but given that abatacept has a half-life ranging from 8-25 days, with an average half-life 
of 13.1 days (117), this was considered not necessary. Also, we were concerned that a higher 
dose and/or a higher dosage interval could lead to an increased frequency of cell death, as we 
had a limited number of cells to begin with.  
 
5.2. The expression of genes involved in the T-cell signalling pathway was overall low 
in resting cells from both AAD patients and healthy controls  
A commercial SYBR green qPCR assay was used to examine differences in gene expression 
between six APS-1 patients, one AAD patient and seven age- and sex-matched healthy controls, 
in genes related to CTLA4-function. No significant differences were found between the groups. 
RNA samples used were obtained from the ROAS registry, all with RIN-values indicating high 
quality RNA (140). The qPCR assay used in this project gives 96 different genes for use in 
analysis (84 after removal of housekeeping genes and control-probes), and one of the most 
interesting in this project is CTLA4. This gene has been shown to be involved in susceptibility 
for developing AAD (115, 116) and is also known to be an important component in the function 
of Tregs (46, 89). In addition, a recent GWAS has shown that polymorphisms in the CTLA4 
gene predispose for development of AAD (Eriksson, Røyrvik and Aranda-Guillen et al., 
submitted manuscript).  From the results (Fig. 10), one can see that CTLA4 has a low expression 
in both patients and controls. This is not a surprise, as it is known that CTLA4 is expressed after 
the T-cell has received a signal from the APC and a following co-stimulatory signal from the 
CD28-CD80/86 interaction (97). To obtain a clearer view of the expression of CTLA4 and other 
genes on the plate, the experiment could have been done on activated cells. However, the 
purpose of this experiment was to select genes of interest to further study in activated cells, as 
we knew the limitation in sample size would only allow us to investigate the gene expression 
of a selected handful of genes.   
 
The initial qPCR assay did not reveal many genes that reached significance when comparing 
expression levels between patients and controls, but the fold change still indicates a difference 
in the expression of certain genes in patients and controls. A p-value of 0.039654 was found 
for FASLG, a gene encoding a protein involved in both thymic and peripheral apoptosis (30-
32), and that was downregulated in  the patients, when compared to the controls (Fig. 10). Due 
to multiple testing, the limit for significance was lowered to 0.01, and the change seen for 
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FASLG was thus not considered significant. From Fig. 10 it is evident that there is a fold change 
value indicating differences in expression of some of the interleukins; IL13 and IL10. We 
speculate that this might be caused by an ongoing infection or that one of the subjects were 
recovering from an infection, as these cytokines, in different ways, are involved in an immune 
response (149, 150), but this information was not available. Also, there was a variation in the 
sample size populations; for IL10 only five patients and two controls are examined for 
differences in gene expression, and the involvement of more patients and controls are necessary 
to validate the findings. Since we used a SYBR green qPCR assay, a melting curve analysis 
could have been performed to ensure that only the specific wanted product was present in each 
sample (151). However, we chose to rely on the quality of the commercial assay used, hence 
no melting curve analysis was done. In general, the differences seen in gene expression might 
not be affected by AAD, but could be due to biological differences between individuals and it 
would have been interesting to examine a larger population. Since the difference was found in 
resting cells, and there is a continuous supply of patient blood samples to ROAS, this would be 
relatively easy to do. To see if there actually is a significant difference or biological relevance 
in gene expression, one has to select the genes with the most promising fold change and run 
further analysis to confirm the results.  
 
5.3. The expression of candidate genes in activated cells, treated or untreated with 
abatacept, was in general low in both AAD patients and healthy controls  
When the gene-expression assay was repeated on activated cells, treated or untreated with 
abatacept, from five AAD patients and five healthy controls, a TaqMan qPCR assay was used 
to explore effects on gene transcription on the selected genes from the resting cell study. We 
did not find significant differences in gene expression of the selected genes CTLA4, FASLG, 
ICOS and JUN within or between the patient and control populations (Fig. 11 and 12). The 
majority of signals appeared late in the qPCR cycle, indicating low gene expression. Fold 
change values did not give significant differences in gene expression after treatment with 
abatacept (Fig. 12), but patient 5 stood out from the remaining samples by showing a higher 
expression of FASLG, ICOS and JUN. Due to the involvement of FASLG and ICOS in the T-
cell mediated immune response (31, 152), a higher expression in patient 5 might be caused by 
an infection at the time of sampling.  
 
Concentrations of RNA in each sample was relatively low and the quality, assessed by the RIN-
value, varied (Fig. 9 and appendix IV). This could be caused by the presence of genomic DNA 
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or the presence of RNases causing degradation of RNA (153), and also because the 
concentrations of the samples challenged the detection limit of the instrument. Due to sample 
size limitations, we had to use the RNA available, regardless of RIN-values or low 
concentrations. A premade TaqMan qPCR assay were chosen based on higher specificity 
compared to a SYBR green assay (154), and because they were pre-tested by the manufacturer. 
We chose to add the housekeeping gene (B2M) to each well, together with the TaqMan enzyme, 
probes (CTLA4, FASLG, ICOS, JUN) and the samples. The housekeeping gene amplified well 
in all samples, thus indicating a functional assay. Despite this, we still experienced problems 
with signals appearing late in the qPCR cycle for the genes of interest. We suspect that this 
could be due to low input RNA or a general low expression of the genes tested, but could also 
have been caused by problems with the probes. Cells used in this qPCR assay were taken from 
specific wells on the plate used for cell culture, and therefore, not only T-cells, but also dead 
cells and all other cells present in a particular sample, were collected. A possibility could have 
been using a type of flow cytometry known as fluorescent-activated cell sorting (FACS) to 
separate live cells, live CD4+ cells or even FOXP3+ Tregs (132), but this would require much 
higher cell numbers than obtained here.     
 
5.4. Treatment with abatacept affected proliferation, the fractions of live cells and cell 
protein expression of T-cell/Treg markers 
Flow cytometry was used to examine cell protein expression and the effect of abatacept on T-
cells/Tregs in AAD. It was decided to use an abatacept-concentration of 20 𝜇g/mL, as this 
concentration showed greatest effect of abatacept in pilot experiments. We saw that treatment 
affects both the fraction of live cells (Fig. 16) and proliferation (Fig. 17 and 18), with statistical 
significance for patients, but not for the controls. Also, we did not find differences between the 
two groups (patients and controls) for any markers of T-cells/Tregs (table 8). Our results 
indicated an overall lower frequency of division when cells were treated with abatacept, in line 
with findings in other studies (119, 155). The exception was patient 5, where a small increase 
in proliferation was observed post-treatment with abatacept. It is difficult to explain why this 
patient stood out, but we do know that it was most likely not due to degradation, as abatacept 
was stored in aliquots to avoid freezing and thawing. Patient 5 also differed from the other 
samples in the qPCR experiment on activated cells (Section 5.3), but we do not know if 
increased expression of FASLG, ICOS and JUN is connected with a slightly increased 
proliferation, after treatment with abatacept. As expected, a decrease in the amount of activated 
cells was observed, as the mechanism of action of abatacept is to inhibit/modulate T-cell 
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activation by interfering with the required co-stimulatory signal (Fig. 19) (117). Also, we used 
the same gating strategy for all samples, and aimed for equal gating for each marker within 
populations analysed at the same time/day, meaning that the same gate was set for CD4 for 
patients and controls no drug and drug. This might have caused a higher frequency of some 
subpopulations, for instance for CD4+CD25+ cells (Fig. 19 (a)), which make up approximately 
10% of the CD4+ cells, while roughly 1-2% these cells have been found to express high levels 
of CD25 and show suppressive properties (67, 156).  
 
We defined Tregs as CD4+CD25+FOXP3+ cells, as it has been shown that FOXP3 is important 
for their development and function (54). We hypothesized an increase in the amount of Tregs 
post-treatment with abatacept, in hopes of suppressing the autoimmune reaction, but we 
observed variation between samples, both for patients and controls, as treatment with abatacept 
resulted in both a higher and a lower frequency of Tregs (Fig. 22). Studies have shown that 
treatment with abatacept/CTLA4-Ig can cause both an increase and a decrease in the 
number/frequency/expression of regulatory T-cells (120, 121, 155, 157), and the results 
obtained here are therefore in line with previous reports, although inconclusive. A decrease in 
the fraction of Tregs could possibly be due to their dependency on CD28 for development and 
maintenance of homeostasis outside the thymus (43-45), as abatacept will inhibit signalling 
through CD28 by binding to its ligands CD80/CD86 on the APC (117). When examining the 
expression of different markers within the Treg population, we did not find significant 
differences between the groups (table 8), but CD39 showed an interesting decrease in 
expression for both patients and controls after abatacept treatment, reaching significance for 
both groups (Fig. 24 (b)). This might indicate a lower frequency of activated Tregs, as CD39 
has been found to be especially expressed on activated Tregs (65). CD39 has also been 
suggested to be involved in the suppressive function of Tregs (69, 70) and a lowered expression 
could indicate altered Treg function as a result of abatacept treatment. More data and 
experiments involving a higher number of patients/controls are necessary to validate these 
findings, before drawing any conclusions.  
 
Regardless of the frequency of Tregs, the protein expression of CTLA4 within this population 
increased for the majority of patients and controls after abatacept treatment, being statistically 
significant for patients (Fig.  23). We speculate that the increased expression might be due to 
the addition of a CTLA4-agonist. Despite an increased expression of the protein, the qPCR 
done on the same cells, revealed low expression of CTLA4 (Fig. 11). If we had an unlimited 
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access to biological material, the experiments should have been repeated and included more 
patients and more cells, to further search for biological significant differences. Also, at the 
starting point for this study, the samples included had already been collected in ROAS, so they 
were not chosen optimally for this particular study. As of today, we do not know if these patients 
have malfunctioning or decreased numbers of Tregs, but interestingly defective Tregs have 
been found in patients with APS-1 and in patients with APS-2, and many of these patients also 
have Addison’s disease (34, 158, 159). 
 
5.5. Production of IFN-𝛄 was altered after treatment with abatacept  
Low expression of the IFN-γ gene was found in the initial qPCR experiment on non-activated 
cells, but the expression seemed to be higher in patients compared to controls (Fig. 10).  
However, we did not include IFN-𝛾 further on in the analysis of expression level tests in 
activated cells because the differences between patients and controls did not exceed our 
“inclusion criteria”. It has previously been shown that treatment with abatacept can cause lower 
expression of the IFN-𝛾 gene in patients with rheumatoid arthritis (160), and RNA expression 
profiling in activated and treated/non-treated cells would have been interesting if we had had 
more material. Instead the production of the cytokine IFN-γ was investigated by an ELISA 
assay on the supernatant from activated cells, treated or untreated with abatacept, from five 
AAD patients and five healthy controls. We found that treated cells, in general, showed 
decreased secretion of the cytokine and the amount of IFN-γ was, in average, largest in the no 
drug samples for both patients and controls (Fig. 25 and 26), in line with the proposed 
mechanism of action of abatacept (117) and findings in other studies (119). This also 
corresponds to the overall decreased rate of proliferation discovered after treatment with 
abatacept and that the T-cells seemed to be more “active” within the patient population 
compared to the control samples.    
 
Levels of IFN-γ in the samples examined were much higher than expected, as some of them 
fell outside the range of the standard curve even with a 1:100 dilution. This might be due to the 
addition of anti-CD3 when preparing the cells for analysis, as this will initiate the signalling 
cascade and activate the cells (20, 161). The concentration could also be higher, for some 
samples, than reported here, as the assay used had a detection limit determined by the standard 
curve (appendix V). We did not know whether patients and controls had an ongoing infection 
or if they were recovering from a recent infection at the time of blood testing, but this could 
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have affected the results, as IFN-γ is involved in the immune response by mediating 
differentiation of effector T-cells and macrophage activation (61, 64).  
 
5.6. Conclusions  
In summary, we have developed a method that can be used to screen the effect of different 
drugs on T-cells in patients with AAD at the KG Jebsen Center for Autoimmune Diseases, with 
the drawback of being quite time consuming. We have seen that abatacept affects cell survival, 
with the frequency of live cells, in general, being lower after treatment, reaching statistical 
significance for the patient population. We also found that abatacept overall causes a decrease 
in proliferation by cell culture and flow cytometry. Treatment with abatacept showed both 
decreased and increased frequencies of Tregs when compared to non-treated samples, thus 
being inconclusive as it varied amongst patients and controls. The overall expression of genes 
involved in the T-cell signalling pathway in resting cells was low, in both patients and controls. 
When examining gene expression before and after treatment with abatacept in activated cells, 
the same was observed for the candidate genes CTLA4, FASLG, ICOS and JUN, in both patients 
and controls. Treatment with abatacept also affected the production of IFN-	γ, which was 
decreased after treatment for the majority of patients and controls.  
 
The study was limited by a low number of participants and the restricted access to biological 
material. We did not find statistical significance in either gene expression nor in the effect of 
abatacept on the majority of the different T-cell subsets and, in particular, Tregs. However, 
statistically significant differences were found in patients for CD39 and CTLA4 after treatment, 
both within the Treg population. For the controls, differences in the fraction of CD39+ cells 
amongst Tregs reached statistical significance. We do not yet know whether these differences 
are biologically relevant and further studies are needed to be able to determine this.  
 
In order to further search for biological relevant differences, validate findings and identify 
possible new treatment strategies, the involvement of more patients, method optimization, and 
screening of several other drugs are required.    
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6. Further work 
As of today, no cure exists for patients with AAD, and we do not know if they have impaired 
function or decreased frequency of Tregs. We chose to examine the effect of abatacept using 
classical and well-established methods, such as flow cytometry, qPCR and ELISA, but could 
have complemented these methods with other protein-level assays, such as mass cytometry 
(CyTOF) (162). When higher cell numbers are available from patients and controls, a further 
approach could be to use fluorescence activated cell sorting (FACS) to separate different T-cell 
subpopulations (132), including Tregs, and maybe perform single cell sequencing on the 10x 
platform (163), to reveal subtle and stable changes due to abatacept/other drug influence. To 
increase statistical power, the assay developed should have been repeated with a higher number 
of study participants to be able to state whether abatacept biologically and relevantly affects 
Tregs and if patients respond differently to treatment compared to controls. It could also be 
interesting to divide patients into groups based on the presence of polymorphisms in the CTLA4 
gene and further examine the effect of abatacept. Another possibility would be to examine the 
expression of different interleukins, such as IL10, which is important for Treg function (37, 
41), by performing for instance an ELISA assay, by flow cytometry or other multiparametric 
assays.  
 
Since AAD has such a great impact on patients’ lives, as they depend on life-long treatment 
and follow-up by the specialized health care system (112), it is of major importance that we 
continue to investigate and try to develop new treatment options. Finding a cure for autoimmune 
disorders, such as AAD, is difficult, as the disease most often has progressed too far upon the 
time of diagnosis (112). Early disease discovery requires screening of risk populations with 
autoantibody assays and genetic testing. This raises ethical questions regarding testing 
otherwise healthy individuals and how this affects their lives, as they might end up feeling 
sick/sicker while waiting for test results. Furthermore, as the screening tools can only predict a 
possibility that the patient will actually get the disease, it might also involve the question of 
whether we should start treatment or not in these persons. It is also important, now and in future 
research, to take ethical use of sample material into consideration, which we believe to have 
managed here, as one blood sample from each study participant has been used to generate a 
great amount of data (cells, RNA, cytokines). With this in mind, it is still important to try to 
find treatment options that can work to prevent disease complications and increase the quality 
of life for these patients.   
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8. Appendix  
8.1. Appendix I 
Additional information about patients and controls 1-5.  
Patient  Sex Age Diagnosis Organ specific 
autoantibodies 
AIRE 
mutation  
IFN-w 
autoantibodies 
1 F 34 AAD 21OH No Negative 
2  M 53 AAD 21OH No Negative 
3  M 35 AAD 21OH No Negative 
4  F 25 AAD 21OH No Negative 
5  M 61 AAD 21OH No Negative 
 
*AAD, autoimmune Addison’s disease; 21OH, 21-hydroxylase 
 
Control Sex Age 
1 F 37 
2  M 53 
3  M 28 
4  F 28 
5  M 54 
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Additional information about patients 6-12.  
 
 
**A, adrenocortical failure; Al, alopecia; HP, hypoparathyroidism; C, candidiasis; E, enamel hypoplasia; V, 
vitiligo; G, hypogonadism; K, keratoconjunctivitis; N, nail hypertropia; M, malabsorption; 21OH, 21-
hydroxylase; 17OH, 17-hydroxylase; NALP5, NACHT leucine-rich-repeat-protein 5; SSC, side-chain 
cleavage enzyme; GAD, glutamic acid decarboxylase 
†, deceased (age in years) 
-, not found 
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8.2. Appendix II 
RNA expression profiling of genes related to immune tolerance and T cell anergy – data for all 
genes. Positive fold change indicates higher expression in patient than in control, a negative 
fold change on the other hand indicates a lower expression in patient than in control. A p-value 
under 0.01 is considered statistically significant.  
 
Gene Fold change P-value Comment 
BTLA 1.08 0.671 B 
CBLB 1.28 0.139 Okay 
CCL3L1 2.39 0.219 A 
CCR4 1.77 0.298 C 
CD27 1.42 0.798 B 
CD28 -1.51 0.853 B 
CD40 1.37 0.555 Okay  
CD40LG -1.68 0.413 B 
CD70 1.12 0.252 Okay  
CDK2 -1.07 0.739 Okay  
CDK4 1.31 0.987 Okay  
CMA1 1.34 0.948 B 
CSF1 1.24 0.603 Okay  
CSF2 1.49 0.323 A 
CTLA4 -1.45 0.488 C 
DGKA -1.08 0.722 Okay  
DGKZ 1.02 0.739 Okay  
EGR2 -1.00 0.484 B 
EGR3 1.19 0.307 B 
EOMES -1.31 0.678 Okay 
FAS 1.11 0.686 Okay 
FASLG -5.06 0.0396 Okay 
FOS -1.55 0.269 Okay 
FOXP1 -1.10 0.575 Okay 
FOXP2 -1.44 0.394 B 
FOXP3 -1.12 0.505 Okay 
GATA3 -2.24 0.333 Okay 
GZMB -1.12 0.937 B 
HDAC9 1.81 0.276 Okay  
ICAM1 -1.09 0.941 A 
ICOS 26.91 - B 
IFNG 3.44 0.475 B 
IL10 6.69 - B 
IL10RA 9.62 - B 
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IL13 -3.71 0.434 B 
IL15 1.70 0.430 Okay  
IL17A - - C 
IL1A -1.13 0.199 Okay  
IL2 -1.27 0.924 B 
IL2RA 159.78 - A 
IL2RB 1.97 0.395 C 
IL31 -1.06 0.586 C 
IL4 1.40 0.321 B 
IL5 -1.21 0.943 B 
IL6 1.21 0.144 Okay 
IL7R -3.81 0.840 Okay 
ING4 1.04 0.825 Okay 
IRF4 -1.70 0.926 B 
ITCH -1.02 0.883 Okay 
ITGA1 1.21 0.345 Okay 
JAK1 1.43 0.915 Okay 
JAK3 4.70 0.337 B 
JUN -4.87 0.559 Okay 
LAT 1.41 0.336 Okay  
LEP 1.01 0.385 B 
LGALS3 -2.55 0.496 Okay  
LTA 4.95 0.337 B 
MEF2A -1.22 0.417 Okay 
NFATC1 -1.27 0.979 Okay 
NFATC2 2.14 0.176 C 
NFATC3 -1.05 0.457 Okay  
NFKB1 1.58 0.0524 Okay 
NHLH2 2.52 0.494 C 
NOTCH1 -1.17 0.847 Okay 
PDCD1 2.70 0.459 C 
PRF1 -1.12 0.673 B 
PRKCG -1.01 0.975 B 
PTGER2 -1.12 0.407 Okay 
PTGS2 -1.26 0.257 B 
RNF128 - - C 
SELL -1.16 0.776 B 
STAT3 -2.59 0.564 Okay  
STAT6 -1.00 0.851 Okay 
TBX21 12.16 0.263 B 
TGFB1 1.04 0.929 Okay 
TNFRSF10A -1.39 0.872 Okay  
TNFRSF14 1.05 0.888 Okay  
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TNFRSF18 -1.02 0.519 B 
TNFRSF4 1.09 0.505 C 
TNFRSF8 -1.07 0.494 C 
TNFRSF9 1.19 0.257 B 
TNFSF10 1.59 0.298 B 
TNFSF14 -2.30 0.223 C 
TNFSF8 5.06 0.172 B 
ACTB - - Okay 
B2M 1.11 0.565 Okay 
GAPDH -1.31 - Okay 
HPRT1 -1.00 0.934 Okay 
RPLP0 - - Okay 
 
***  A – High threshold level in either patient or control and low in the other. 
B – High threshold level, low expression in both patient and control. P-value > 0.05. 
C – Average threshold not determined or greater than the cut-off value in both patient 
and control. Expression not detected and fold-change result are erroneous. 
-, no fold change/p-value obtained. 
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8.3. Appendix III 
Number of cells obtained from samples used in isolation of PBMC. Five were chosen as 
controls in cell culture, flow cytometry, qPCR and ELISA assays (marked blue). 
 
Number  Sex Year of birth Cell count x 106 
62 M 1985 0.500 
63 M 1970 0.100 
73 M 1978 0.270 
74 M 1965 0.380 
75 M 1969 0.497 
76 M 1978 0.619 
80 F 1997 2.85 
83 M 1990 8.30 
84 M 1971 4.80 
85 F 1992 8.20 
88 M 1980 1.71 
89 M 1998 2.33 
90 F 1981 2.93 
91 F 1999 1.12 
92 M 1960 4.52 
93 F 1983 3.92 
94 M 1963 1.24 
95 M 1968 1.76 
96 M 1950 2.83 
97 M 1953 3.54 
98 M 1992 2.98 
99 F 1971 4.42 
100 F 1978 3.01 
101 M 1975 1.71 
147 M 1966 5-10 
149 M 1967 5-10 
208 M 1992 3.47 
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8.4. Appendix IV 
Obtained RNA concentrations and RIN values for patients and controls 1-5.  
 
 RNA concentration  
[ng/𝝁𝑳] 
RIN values 
 No drug 
patient 
Drug 
patient 
No drug 
control 
Drug 
control 
No drug 
patient 
Drug 
patient 
No drug 
control 
Drug 
control 
1 11.62 6.56 56.69 2.58 6.30 6.70 4.60 - 
2 39.60 61.83 13.72 5.23 5.90 6.80 6.70 6.70 
3 4.36 0.85 4.10 1.07 8.0 - 7.70 4.60 
4 4.11 7.71 4.34 4.56 - - 6.60 5.80 
5 5.42 1.33 6.22 3.35 6.60 5.60 9.10 9.20 
 
**** -, no RIN values obtained due to low sample volume.   
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8.5. Appendix V 
Standard curve from one of the performed ELISA assays.  
 
Appendix V figure 1: ELISA standard curve. An example of a standard curve taken from one of the ELISA assays 
performed. The curve is made based on declining concentrations of a standard solution, including a blank sample. 
For each assay a new standard is run. R2 equals one, indicating a perfect standard curve. Concentrations of IFN-
g could be calculated from the curve, but in this case the software provides these values directly. Samples that fall outside 
the range of the standard curve most likely need to be reanalyzed at a higher or lower concentration.   
  
  
Conc
1 10 100 1000
0
0,5
1
1,5
2
2,5
StandardCurve
4-P Fit: y = (A - D)/( 1 + (x/C)^B ) + D: A B C D R^2
STD#1 (Standards: Conc vs AvgOD) 0.035 1.16 257 4 1
__________
Weighting: Fixed
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